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3Abstract
Articular cartilage is a highly specialised tissue composed of a mechanically competent
matrix and a single cell population– the chondrocytes. The maintaining of a specialised
phenotype requires the integration of intracellular signalling, that in response to appropriate
extracellular stimuli, results in expression of cell-specific genes. Previous work in our
laboratory has identified hypoxia as one such key stimulus, which through HIF-2?? enhances
expression of cartilage master regulator SOX9 and its matrix-encoding target genes
(COL2A1, AGC and COL9A1).
MEF2C transcription factor is known to be involved in muscle and cardiovascular
development; however, recently it has been shown to play a key role in chondrocyte
hypertrophy co-ordinately with SOX9. In a previous microarray analysis, we found that
MEF2C was upregulated during hypoxia-induced re-dedifferentiation of human articular
chondrocytes (HACs); interestingly where its suggested genetic target - COL10A1 - was
barely detectable. In this research we therefore investigated a possible new and unknown
function of MEF2C transcription factor as a potential genetic regulator of the permanent
articular chondrocyte phenotype.
In this study, MEF2C protein was detected with a nuclear localisation in chondrocytes in situ
in intact healthy human articular cartilage. Experiments in isolated HACs revealed that, at
both gene and protein levels, hypoxia enhances MEF2C expression in a HIF-2? and SOX9
dependent fashion. Subsequently, depletion experiments of MEF2C indicated that it is
required for SOX9 gene expression both in normoxia and hypoxia. Our results, therefore
suggest a mutual positive regulation between MEF2C and SOX9 transcription factors in
articular cartilage.
Thus, based on our studies a new and critical function for transcription factor MEF2C in
HACs has been identified, where it helps promote expression of the differentiated
chondrocyte phenotype through mutual regulation with SOX9. These findings give important
new insights into our understanding of the transcription factor networks that regulate
expression of the articular chondrocyte phenotype.
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1.1 The synovial joint
Locomotion is made possible by the harmonious coordination of the different components
of the musculoskeletal system. In this elegant and complex system the synovial joint is
responsible for the ease of movement between articulating bones. The synovial joint is the
most common type of joint in our bodies and shows a diversified array of shapes and sizes,
e.g. the femoral joint (femoral spherical convexity in the hip concavity) and the phalangeal
joint (two condyles articulating in reciprocally-shaped sockets on the opposing proximal side)
(Pacifici, Koyama et al. 2006). Despite this variety, the synovial joints of mammalian bodies
show the same general organization. The end of the adjacent bone is covered by smooth layer
of articular cartilage (hyaline cartilage) which is lubricated and fed by the synovial fluid
(FIG. 1.1). The synovial membrane or lining is responsible for the production of the synovial
fluid and restricts the movement of large molecules, allowing just water, small molecules and
metabolites to freely pass (Sophia Fox, Bedi et al. 2009). Another relevant contribution of the
synovial membrane to the physiology of the synovial joint is the presence of the “type A” and
“type B” synoviocytes on the luminal surface (intima) (Iwanaga, Shikichi et al. 2000). The
“type B” population actively helps to control the protein concentration in the synovial fluid.
They are responsible for the secretion of proteins such as collagen or glycosaminoglycan
such as hyaluronic acid into the joint cavity (Sophia Fox, Bedi et al. 2009). The “Type A”
population, a macrophage cell population that has antigen-presenting activity, is a “not-fixed
cell population” that can actively phagocytise cell debris in the joint cavity (Iwanaga,
Shikichi et al. 2000).
The articular cartilage and synovium are surrounded by a fibrous membrane that isolates
them from the adjacent tissue, while the ligaments hold the skeletal elements together
(Pacifici, Koyama et al. 2006).
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FIGURE 1.1. Schematic representation of a normal, healthy synovial joint. The diarthrodial joint
connects two bone epiphyses, covered by articular cartilage and lubricated by synovial fluid which
allows their reciprocal movement. The bony elements are held together by ligaments and muscles
(modified from Tamer 2013).
1.1.1 Articular cartilage
A unique feature of the synovial joint is the presence of articular cartilage. This
relatively thin, avascular and aneural layer of hyaline cartilage has the ability to persist
throughout life with minimal turnover of its cells and matrix components (Nelson, Fairclough
et al. 2010).
The articular cartilage is a highly specialized tissue composed of a mechanically
competent matrix which is produced and maintained by a relatively low number of a sole cell
population, namely chondrocytes (Pacifici, Koyama et al. 2006). The extracellular matrix
(ECM) consists of an abundant amount of collagens that provide a network in which other
large macromolecules, such as proteoglycans, are connected (Bora and Miller 1987). The
large proportion of water, drawn into the tissue by the presence of negatively charged
proteoglycans, and the interaction among collagens and other proteins, give articular cartilage
the capability to resist both compressive and tensile forces (Sophia Fox, Bedi et al. 2009).
Articular cartilage is organized in four distinct zones: the superficial, middle, deep and
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calcified zones (FIG. 1.1.1). From the superficial to the calcified zone the shape and
orientation of the chondrocytes change following the architecture of the collagen fibres.
Small and flattened chondrocytes of the superficial zone are replaced by spherical
chondrocytes of the middle zone which increase in size in the deep zone. Despite a low cell
density, adult articular cartilage presents a fine regulation between synthesis and degradation
of its ECM orchestrated by the articular chondrocyte (Nelson, Fairclough et al. 2010).
FIGURE 1.1.1. Structure of articular cartilage. A schematic representation of articular cartilage in
four distinctive zones with orientation of the chondrocyte population highlighted (A) and of the
collagen fibre architecture (B) (modified from Buckwalter, Mow et al. 1994). Note: STZ – superficial
transition zone.
1.1.2 Articular chondrocytes
The chondrocyte is the only cell type present in the articular cartilage and as such is
solely responsible for its formation and functional maintenance (Lin, Willers et al. 2006).This
sparse cell population represents approximately only 5-10% of the total articular cartilage
volume and is normally contained in cavities of the ECM named lacunae. Electron
microscopy studies revealed that the articular chondrocyte usually has a rounded/oval
nucleus, extended Golgi body and occasionally lipids droplets (Lin, Willers et al. 2006) (FIG.
1.1.2). Articular chondrocytes are biosynthetically active; however they have adapted their
energetic metabolism to the hypoxia conditions they reside in. As a consequence, their entire
energetic requirements are provided by glycolytic metabolism which results in a limited
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number of mitochondria (Archer and Francis-West 2003). The articular chondrocyte is
dynamically involved in bone growth and in the maintenance of matrix homeostasis in
cartilage. In fact, during endochondral ossification or when new cartilage matrix is being
synthesised, the cytoplasm becomes more basophilic and the Golgi unusually large (Lin,
Willers et al. 2006). The gene expression hallmark of articular chondrocytes is the abundant
transcription of collagen type II and the transcription factor SRY (sex determining region Y)-
box 9 (SOX9). This DNA-binding protein, in coordination with other members of the SOX
family, drives the expression of the most important genes of the extracellular matrix. The
matrix genes Col2a1, Col9a1, Col11 and Agn (Aggrecan) have been shown to be direct Sox9
targets in murine studies (Lefebvre, Huang et al. 1997, Lefebvre, Li et al. 1998, Bi, Deng et
al. 1999, Sekiya, Tsuji et al. 2000, Zhang, Jimenez et al. 2003, Genzer and Bridgewater 2007,
Liu, Zhang et al. 2007). Historically, SOX9 has been demonstrated to be essential for the
development and maintenance of murine cartilage and shown to be a possible genetic cause
of the disease called campomelic dysplasia in humans (Foster, Dominguez-Steglich et al.
1994, Meyer, Sudbeck et al. 1997, Bi, Deng et al. 1999).
FIGURE 1.1.2. The articular chondrocyte. The typical articular chondrocyte is normally rounded
containing a large nucleus and rough endoplasmic reticulum, juxtanuclear Golgi apparatus and
deposits of glycogen and lipid droplets (modified from Archer and Francis-West 2003).
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1.1.1 The extracellular matrix (ECM)
The articular cartilage extracellular matrix presents a regional variation in addition to
the zonal variation above mentioned. This classification is based on composition of the ECM
and collagen fibril organisation in proximity of the chondrocytes (FIG. 1.1.3) (Sophia Fox,
Bedi et al. 2009). Accordingly, in the articular cartilage we can distinguish the pericellular,
territorial and interterritotial region of the ECM. First studied by Benninghoff in the 1925, the
pericellular region is a thin layer that surrounds the chondrocytes and is characterised by high
concentration of proteoglycans (aggrecan,, decorin), glycosaminoglycans (hyluronan) and
Collagen 2,3,4,6 and 9 (Poole 1997, Vonk, Doulabi et al. 2010). This region is thought to be
important for the transduction of the mechanical-stress signalling associated with load
bearing (Alexopoulos, Setton et al. 2005). The territorial matrix that surrounds the
pericellular matrix presents a peculiar organisation of collagen fibrils that forms a basket-
like-network which protects the cells from mechanical stresses and contributes to the integrity
of the articular cartilage (Sophia Fox, Bedi et al. 2009). The interterritorial region, the largest
of the articular cartilage regions, is characterised by high abundance of proteoglycans and the
presence of large collagen fibrils. Those, depending on their zonal localisation can be parallel
(superficial zone), oblique (middle zone) and perpendicular (deep zone) with respect to the
joint surface.
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FIGURE 1.1.3. Articular cartilage ECM. The regional organisation of the extracellular matrix
surrounding the articular chondrocyte (Chondrocyte) includes pericellular glycocalyx (Pg),
pericellular capsule (Pc), territorial matrix (Tm) and interterritorial matrix (Im) (modified from Poole
1997).
1.2 Transcriptional control of the human articular chondrocyte (HAC)
phenotype
Operating in a diverse range of microenvironments, cells of the human body have
different energetic requirements. Human bronchial epithelial cells experience an oxygenation
level comparable to the atmosphere, while articular chondrocytes are embedded in an
avascular matrix and rely on diffusion from the vascularised bone and the synovial fluid for
oxygen and metabolites (Chi, Wang et al. 2006).
Metazoans have dedicated systems, namely the cardiovascular and respiratory systems, to
acquire and deliver adequate amounts of oxygen to cells and tissues (Kaelin and Ratcliffe
2008). In addition, cells have developed a molecular “sensing” pathway in order to measure
the oxygen availability and, when it is insufficient, promote the expression of pro-survival
mechanisms (Kaelin and Ratcliffe 2008). At a cellular level, the general response to lower
oxygen levels involves resetting the energetic metabolism, favouring glycolysis for the
production of ATP, and at a gene expression level, the up-regulation of genes that encode for
glycolytic enzymes and glucose transporters (Lendahl, Lee et al. 2009). On other hand, at the
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tissue level there is often a response characterised by de novo angiogenesis, enhanced
vascularisation and haematopoiesis via the up-regulation of the angiogenic factor vascular
endothelial growth factor A (VEGFA), and erythropoietin (EPO) (Lendahl, Lee et al. 2009).
“Acute” hypoxia has been linked directly with pathophysiological manifestations, e.g. during
myocardial infarction, coronary heart disease, or with the “re-oxygenation injury” typical of
ischemia (Semenza 2001, Harris 2002). Longer term, “chronic” hypoxia contributes to
genetic and phenotypical changes in tumours that can lead to the selection of a malignant
phenotype during tumourigenesis (Harris 2002).
Articular cartilage originates from the cartilage template during limb development, which
progressively differentiates, degenerates and is completely replaced by mineralised bone
tissue (Kronenberg 2003). It represents the remains of the differentiating hyaline template
that resits terminal differentiation and blood vessel invasion (Poole 1997). Articular
chondrocytes rely on the supply of metabolites and oxygen from the surrounding tissues. The
most important contributor of metabolic supply of the articular cartilage is the synovial fluid.
The synovial membrane continuously filters metabolites and oxygen form the blood plasma
through the synovial capillaries, and secretes a concentrated fluid enriched with lubricating
molecules (synovial fluid) that reaches the articular cartilage inner layers thanks to the flow
induced by the movements of the joint itself (Levick 1995). The first studies aimed at
measuring the oxygen levels in the synovial fluid, found that a variation of 3.3-9.5% partial
oxygen pressure (pO2) is a characteristic of the rabbit knee (Ferrell and Najafipour 1992).
However, the human synovial fluid shows an average of 4.1-8.9 % O2 in osteoarthritic joints
(Lundoles.K 1970, Richman, Su et al. 1981) and in a variety of traumatic joint diseases
between 5.5-11% O2 (Lundoles.K 1970). Consequently, we can assume that the chondrocytes
of the articular surface which are in direct contact with synovial fluid, experience an average
O2 of 6%. Differently from the superficial chondrocytes, the deeper layer cells experience
much lower levels of oxygen. In their studies, Silver and Maroudas measured the oxygen
levels of 0.5 mm cartilage cubes of rabbit articular. Using a microelectrode they calculate that
at the centre of cartilage cubes there was oxygen levels within a range of 0.6-1% (Silver
1975). The real contribution of the subchondral bone as a source of oxygen and nutrients to
the adult cartilage is still controversial. Despite the fact that endochondral bone is physically
interacting with the deepest layers of the articular cartilage and is vascularised, it is hardly
permeable (Zhou, Cui et al. 2004) which leads us to assume that its contribute to the
oxygenation of the articular cartilage may not be appreciable.
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1.2.1 The HIF Pathway
Hypoxia Inducible Factors (HIFs) are at the centre of the oxygen sensing system in
mammalian cells. HIF transcription factors are DNA-binding proteins that, in collaboration
with co-activators, can trigger the expression of genes involved in oxygen homeostasis. First
identified by Semenza in 1992, HIF is a heterodimer comprising of subunits that are part of
the bHLH-PAS family (Semenza and Wang 1992). HIF complexes comprise an oxygen-
?????????? ???????? ???????? ?????? ??????????????? ?????????? ????????? ????????????????? ?????????
???????? ????????????????????????????????????????????? ?????????????????????????????? is
stable and can dimerise with the ? subunit before translocation to the nucleus where it binds
specific genomic sequences named Hypoxia Response Elements (HRE), characterised by the
sequence RCGTG (Semenza, Jiang et al. 1996). The transcriptional activity of HIFs is aided
by the interaction with co-activator p300, CREB Binding Protein (CBP) or recruitment of
chromatin modification enzymes (Lendahl, Lee et al. 2009).
In the last decade further genes (in addition to HIF-1??? ????????????????????????????
????????? ????? ????? ??????????? ?? ??????? ???? ?????? (Tian, McKnight et al. 1997, Hara,
??????? ??? ???? ????????????????????????? ???? ????????? ???????????? ??????????????? ????????
subunits, and both present transactivation domains (TAD), traditionally divided into N-
terminal transactivation-domain (NTAD) and C-terminal transactivation-domain (CTAD). In
????????????????????????????????????????????????? ?????????????????????????????????????????
subunits become hydroxylated by prolyl hydroxylase domain enzymes (PHD1, PHD2, and
PHD3). The hydroxylation creates two binding sites for a component of the ubiquitin ligase
complex, von Hippel-Lindau protein (pVHL), which results in degradation by the 26S
proteasomal complex (Kaelin and Ratcliffe 2008) (FIG. 1.2.1).
The PHD enzymes belong to the superfamily of the Fe (II) and 2-oxoglutarate-
dependent oxygenases, and their activity is strictly oxygen-dependent. PHDs use molecular
oxygen to catalyse the oxidative decarboxylation of the 2-oxoglutarate to succinate and CO2.
During this reaction the hydroxylation of prolyl residues on the HIF subunit is coupled with
splitting of the molecular oxygen via the formation of a highly reactive ferryl intermediate
that oxidases the prolyl amino acid residues. In addition to limiting oxygen levels, a decrease
in the availability of these cofactors could change the hydroxylation of HIFs causing their
stabilisation (Schofield and Ratcliffe 2004).
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Another relevant player of the oxygen sensing system is the Factor Inhibiting HIF
(FIH). FIH, as well as PHDs, is a member of Fe (II) and 2-oxoglutarate-dependent oxygenase
family, but it hydroxylates a conserved asparaginyl residue within the CTAD, preventing the
recruitment of the co-activators p300 and CBP (Kaelin 2005). Another important difference
between FIH and PHDs is that the former remains active at relatively lower oxygen
???????????????? ????? ???????? ??? ???? ????????????? ??? ?????? ????????? ????? ????? ???????? ????
??????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????? (Schofield and Ratcliffe 2004, Kaelin and Ratcliffe 2008).
???????????????????????????? ???????????????. Note: PHD – prolyl hydroxylase domain
enzyme; pVHL – von-Hippel–Lindau-tumour-suppressor protein; FIH – factor inhibiting HIF; Pro –
proline; Asn – asparagine.
1.2.1.1 The different HIF isoforms
??????? ???? ???? ?????? ?????? ???????? ??? ??? ??????????? ??? ?? ????????? ??? ????
transcriptional response to hypoxia (Semenza, Nejfelt et al. 1991, Wang, Jiang et al. 1995). In
????????????????????????????????????????????????????????????????????????????????????????????
to be restricted to the vascular endothelium, it was subsequently found to be expressed in
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?????????? ????? ?????? ???? ??? ??? ????????????????????????? ?????? ????? ??? ???? ?????? ????????
Frohlich et al. 1997, Hogenesch, Chan et al. 1997, Tian, McKnight et al. 1997, Wiesener,
Jurgensen et al. 2003). Both HIFs possess an N-terminal basic helix-loop-helix (bHLH)
domain, an intermediate PAS domain, an N- and C-terminal transactivation domain
(respectively NTAD and CTAD). Both HIF-? isoforms share a high protein homology (48%)
which is more informative if we analyse the individual functional domains. The bHLH
domains shares 83% homology, while the PAS, NTAD and the CTAD domains, are 70%
homologous between isoforms (Ema, Taya et al. 1997).
???????? ????? ????? ?????????? ?????? ????????? ????? ?? ???????? ??????????? ?????? ????
oxygen tension with substantial differences in the amino acid residues subject to
hydroxylation. In NTAD domains, the hydroxylation occurs on Pro402 and Pro564 for HIF-
????????????????????????????????????? (Keith, Johnson et al. 2012). A similar difference is
???????????????????????????????????????????????????????????????????????????????????????
position 847 (Simon and Keith 2008). Moreover, the CTAD domain is the centre of
???????????? ????? ???? ?????? ???? ????? ?????? ??? ??? ????? ?????????? ??? ??????????? ???????
compared to HIF-1? (Yan, Bartz et al. 2007). FIH is active at lower oxygen levels, and as a
???????????????????????????????????????????????????????????????????????????????????????????
1?) to expression of genes exposed to greater levels of hypoxia (Kaelin and Ratcliffe 2008).
????????? ??????? ???????? ??? ??? ?????????? ??? ???????? ??????????? ??? ????????
????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????? ???????????
2003, Keith, Johnson et al. 2012). Recently it has been demonstrated, by swapping of the
???????????????????????????????????????????????????????? ????? ???????????????????????????
?????? ???????? ??? ???? ?????????? ??? ?????????? ???????????? ??????????? ???? ???????? ???
differences in the transactivation domain of these proteins (Hu, Wang et al. 2003, Lau, Tian
??? ???? ??????? ???????? ??? ????? ?????? ????????????????????? ??????????? ????? ?????? ???? ????
latter is less active or its binding to a functional HRE leads to unproductive transcription (Hu,
Wang et al. 2003). Subsequently, ChIP-Seq experiments revealed that some of the HRE
?????????? ???????? ??? ???? ??????? ???? ?????? ??????????????? ??? ??????? ??? ??????? ?????????
others to both HIFs (Schodel, Oikonomopoulos et al. 2011, Keith, Johnson et al. 2012). The
high levels of protein found in most of the HRE sequence suggest that the role of co-factors,
post-translation modification, and cell-specific chromatin conformation can play a pivotal
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role in the target gene expression (Xia and Kung 2009, Schodel, Oikonomopoulos et al.
??????? ?????????????? ??????? ???? ??????? ????? ????? ?????? ??? ????? ??? ??????? ???????
??????????????? ??????? ???? ????? ?????? ??????????? ????? ???? ????????? ??? ?????? ????????? ???
glycolysis such as HK1-2, PFK, ALDOA, PGKI and LDHA (Iyer, Kotch et al. 1998, Ryan,
?????? ???? ?????????????????? ???? ?????????????????? ??????????????????????????????? ???????
??????????????????????????????????????????????????????????????????????? (Raval, Lau
et al. 2005, Gilbertson and Rich 2007, Gruber, Hu et al. 2007, Skuli, Liu et al. 2009).
Despite the fact that the major part of the hypoxia transcriptional response has been
????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????? ????????????????????????????????
the same organisation as the other HIFs, however it crucially lacks of the CTAD domain (Gu,
?????? ??? ???? ?????? ?????? ?????????? ??????? ??? ?????? ?????? ???? ????????? ????????????????? ???
encoded by the HIF3A? ????? ???? ???? ??????????? ?????????? ??????????????????????????????????
can still bind to HRE sequences and form an inhibition complex. In particular, it is thought to
????? ????????????? ?????????? ???? ??????? ???? ???????????????? ????????? ????????????????? ??? ????
2002).
FIGURE 1.2.1.1. Domain structures of the HIF transcription factors.? ???????? ??????? ????
??????? ???????? ???????? ??????? ??? ????? ???????? ????? ???? ???? ????????? ?????? ???? ?? ???????
degradation domain; N-TAD – N-terminal transactivation domain; C-TAD – C-terminal
transactivation domain. Numbers and letters refer to the amino acid residues hydroxylated on proline
(P) and asparaginyl (N) residues (modified from Keith, Johnson et al. 2012).
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1.2.2 Cartilage master transcription factor SOX9
The SOX9 transcription factor is essential for the survival of the differentiating
chondrocyte and for chondrocyte differentiation process itself (Lefebvre, Huang et al. 1997,
Bi, Deng et al. 1999, Dy, Wang et al. 2012). A most important role of SOX9 was suggested
by Foster JW and colleagues in 1994. Heterozygous mutation at the human SOX9 gene locus
was directly associated with a human autosomal disease, campomelic dysplasia, characterised
by individuals with severe skeletal malformations, scoliosis, cervical spine flexure and sexual
reversibility (Foster, Dominguez-Steglich et al. 1994). SOX9 has been identified as the first
transcription factor essential for the skeletal development (Bi, Deng et al. 1999). The first
study aimed at clarifying SOX9 involvement in cartilage formation was carried out by Bi and
co-workers. Using Sox9-/- mice the authors showed that mice lacking Sox9 completely failed
to form bone, revealing that SOX9 protein is required for skeletal development (Bi, Deng et
al. 1999). In fact, mesenchymal progenitors lacking Sox9 fail to differentiate towards the
chondrocyte phenotype and form a skeletal-like structure (Bi, Deng et al. 1999). Furthermore,
experiments using conditional homozygous knockout mice for Sox9 have shown that the
expression of Sox9 is required both at the early mesenchymal condensation stage and the late
stage of the chondrocyte differentiation, namely hypertrophy in the growth plate (Akiyama,
Chaboissier et al. 2002, Akiyama, Kim et al. 2005, Dy, Wang et al. 2012).
SOX9, together with transcriptional partners SOX5 and SOX6, is responsible for gene
transcription of the most important cartilage ECM components: Collagen2, 9, 27, Aggrecan,
Matrilin-1 and Cartilage oligomeric protein (COMP)(Liu, Zhang et al. 2007) (Bell, Leung et
al. 1997, Ng, Wheatley et al. 1997, Lefebvre, Li et al. 1998, Huang, Zhou et al. 2000, Sekiya,
Tsuji et al. 2000, Huang, Lu et al. 2002, Jenkins, Moss et al. 2005, Genzer and Bridgewater
2007, Dy, Wang et al. 2012) (Ng, Wheatley et al. 1997).SOX9 exerts its function as a
transcription factor by binding to an heptameric sequence (A/T)(A/T)CAA(A/T)G through a
high mobility group (HMG)-box domain (Oh, Maity et al. 2010). It seems that the formation
of homodimers is required for the expression of cartilage related genes (Bernard, Tang et al.
2003).
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The regulation of the SOX9 protein in the context of chondrocyte biology is not
clearly elucidated and it has been studied mostly in murine models. The expression of SOX9
protein is stimulated principally by the FGF and PTHrP signalling pathways (Murakami, Kan
??????????????????????????????????????????????????????????????????? ???????????????????????
?????????????????????????????????????????????????????????????????????????????????
Developmental studies and the use of the genetically manipulated mice have provided
a great impulse to the comprehension of cartilage biology. However, the role and the
regulation of SOX9 function in postnatal and adult cartilage is still unclear. In adult mice, it
has been recently demonstrated that SOX9 transcription factor is required for chondrocyte
survival in articular cartilage where it governs a large genetic programme involving the
transcription of genes encoding for membrane receptors, ECM proteins and metalloproteases
(Henry, Liang et al. 2012).
In human adult articular cartilage, SOX9 is the master regulator of the ECM genes
such as Aggrecan, Col2a1, Col9a2 (Lafont, Talma et al. 2008) and it appears to show a fine
regulation of its post-transcriptional regulation involving a network of micro-RNAs (Dudek,
Lafont et al. 2010, Martinez-Sanchez, Dudek et al. 2012, Martinez-Sanchez and Murphy
2013) expression is enhanced by HIFs and PTHrP (Lafont, Talma et al. 2007, Thoms, Lafont
et al. 2009, Pelosi, Lazzarano et al. 2013).
1.2.3 HIF signalling and control of the chondrocyte phenotype
Together with its involvement in maintenance of metabolic activity, an important role
???????????????????? ????????????????????? ??? ????????????????????????????????????? (Lafont
2010). During endochondral ossification, the new bones develop from a cartilaginous
template (Kronenberg 2003). The population of chondrocyte is well adapted to the hypoxic
environment where they are able to survive, differentiate and provide important stimuli for
the growth and vascularisation of the new bones ?????????????????????????????????????-/- and
??????-/- mice display an embryonic lethal phenotype underling the importance of this
pathway during development (Kozak, Abbott et al. 1997, Compernolle, Brusselmans et al.
2003). Using a conditional knockout model, it has been demonstrated that in absence of HIF-
??? ?????? ?????????????????????? ??? ???? ?????? ????? ???????????????????????????????? ???????????
plate ?????????????????????????????????????????????????????????????????????????????????????????
a decreased expression of the CDK inhibitor p57 in differentiating chondrocytes (Schipani,
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???????????????????????????????????????????????????????????????????????????????????????????
ossification process where it contributes to collagen type II metabolism. Prolyl hydroxylation
is an important step for the correct synthesis of the collagen triple helix, and the increase in
prolyl hydroxylase levels observed in hypoxia could give an important contribution to the
ECM biology through post-translation modification of cartilage collagen (Pfander, Cramer et
???? ?????????????????????? ????????? ????????? ??????? ???????????? ??? ???? ?????????? ????????
from chondrocytes, which provides a pro-survival stimulus and promotes vascularisation and
vessel invasion from the perichondrium (Gerber, Vu et al. 1999, Cramer, Schipani et al.
2004).
? ???????????????????????????????????????????????????????????????????????????????????
Unlike HIF-1?-/- mice, HIF-2?-/- (i.e. EPAS1-/-) deletion in mice is not embryonic lethal,
although they do have substantially a shorter lifespan, presenting with cardiac hypertrophy,
hepatomegaly, and pancytopenia (Tian, McKnight et al. 1997, Peng, Zhang et al. 2000,
????????????? ??????? ??? ???? ?????? ??????? ?????? ??? ???? ??????? ???? ????? ??? ??????? ???????
endochondral ossification was clarified by Araldi and colleagues. Murine models, where the
Prx1-promoter driven-Cre cassette was used to conditionally inactivate the heterozygous
EPAS1 floxed allele during mesenchymal budding, showed only a minor delay in
endochondral bone development (Araldi, Khatri et al. 2011).Those reports underline the
importance of the HIF pathway during embryonic development with a critical involvement
?????????????????????????????????????????????????????? ?????
1.2.4 Regulation of the HAC phenotype: the role of HIFs
Despite the large number of studies that have been performed to understand the effect
of the HIF pathway in developing chondrocytes, the role of HIFs in human adult cartilage is
less well known. As aforementioned articular cartilage is avascular and, at least in larger
animals where diffusion distances are limiting, experiences chronic hypoxia throughout life.
?????????????????????????????????????????????????????????????????????????????????????????????
???????? ?????? ???? ??????????????? ?????????? ?????????? ???????? ??? ???? ?????? ??????????
Terkhorn et al. 2009). The first experimental evidence aimed at studying the involvement of
????? ??? ????? ???????? ?????????? ?????? ??? ??????????????? ???????? ???? ??????? ????????????????
activity was increased with a lowering of oxygen partial pressure (Grimmer, Balbus et al.
2006). Yudoh and colleagues investigated human articular cartilage of osteoarthritic (OA)
Chapter 1 Introduction
34
patients and reported that HIF-1? expression was higher in degenerated regions compared
??????????????????????????????????????????????????????????????????????????????????????????????
????????? ???? ????????? ????????? ???? ???? ??????????????? ?????????? ??? ????? ??????? (Yudoh,
????????????????????????????????????????????????????????????????????????????????????????
important anti-catabolic role in HACs mediating the expression of metalloprotase inhibitor
TIMP-3 and the suppression of collagenase MMP-13, largely involved in the destruction of
articular cartilage in OA (Thoms, Dudek et al. 2013). In addition, an inflammatory signal in
??????????????????????????? ?????????????????????????????????????????????????????????????
(Coimbra, Jimenez et al. 2004, Fujita, Markova et al. 2012). Hence, the reports present in the
??????????? ???????? ????? ??????? ??????? ?? ????????????? ??????? ??? ?????????? ????????????? ???
response to catabolic stress.
Hypoxia promotes the expression of cartilage matrix genes in bovine and adult HACs,
with similar results in meniscal cells (Murphy and Sambanis 2001, Domm, Schunke et al.
2004, Adesida, Grady et al. 2006). However, the mechanism by which hypoxia can increase
the expression of the matrix related genes was further clarified by Lafont and co-workers.
???? ?????????????? ??????? ??????? ???? ????? ?????? ??? ????????? ????????? ???? ??????????? ??? ????
COL2A1 and ACAN genes via the up-regulation of the master regulator SOX9 (Lafont,
?????? ??? ???? ??????????? ???????? ?????????? ?????????????? ??????? ??? ??????????????????????
subsequently proposed by Robins and colleagues in mouse pluripotent stem cells and was not
linked with an increase of the SOX9 protein (Robins, Akeno et al. 2005). Finally, Thoms and
????????????????????????????????????????????????????????????????????????????????????????
??? ????? ???????? ?????? ??? ???? ??????? ???? ??????? ??????????? ???? ????????? ??? ????
transcriptional machinery or which kind of co-activators or additional transcription factors
are involved in SOX9 transcription is still a question mark.
Besides direct control of SOX9 gene transcription (via HIF-2?), hypoxia can regulate
HAC gene expression via specific non-coding-RNAs. Hypoxia upregulates, via SOX9 itself,
the expression of the long-non-coding RNA H19 and its processed microRNA miR-675
which upregulates type II collagen (Dudek, Lafont et al. 2010). SOX9 also regulates
expression of miR-140, another important microRNA in cartilage (Nakamura, He et al. 2012)
(Miyaki, Sato et al. 2010). Unpublished work in our laboratory has revealed that miR-140 is
hypoxia inducible in HACs. Interestingly, the expression of SOX9 mRNA is itself directly
influenced by two other micro-RNAs: miR-145 and the miR-1247. These miRNAs contribute
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to the creation of a genetic circuit that aims to regulate the levels of the SOX9 protein in
human articular chondrocytes (Martinez-Sanchez, Dudek et al. 2012, Martinez-Sanchez and
?????????????? ??????????????????????????????????????????????????? ??????? ?????? ?????? ????
SOX9 mRNA and at the same time to be negatively regulated by SOX9 itself, creating a
negative feedback loop (Martinez-Sanchez and Murphy 2013). The other miRNA, miR-145,
????? ????????? ???????? ????? ????? ???? ????? ?????????????? ??? ??????? ??????????????? ???? ???
shows an increased activity in low oxygen conditions (Martinez-Sanchez, Dudek et al. 2012)
(FIG. 1.2.4).
Although several studies have been performed to understand the intimate mechanisms
of the individual regulatory pathways, only one has described the global effect of hypoxia on
the chondrocyte transcriptome. Lafont and colleagues identified 101 genes upregulated by
hypoxia and potentially relevant for expression of the differentiated HAC phenotype (Lafont,
Talma et al. 2008). In this unbiased study, potentially relevant genes were identified among
those that were both downregulated by dedifferentiation (by serial passage in normoxic
conditions) and subsequently upregulated by hypoxia. Besides the already established
chondrocyte markers identified by this method (i.e. SOX9, ACAN, cartilage collagen genes),
new potentially functionally important genes were found such as additional matrix genes,
growth factors, transcription factors, long non-coding RNAs (H19) and microRNA primary
transcripts (miR-140 encoded within the WWP2 gene) (Lafont, Talma et al. 2008).
Transcription factors identified included DEC-1, DLX5 and MEF2C and these were shown
by others to be upregulated by hypoxia (Robledo, Rajan et al. 2002, Arnold, Kim et al. 2007,
Verzi, Agarwal et al. 2007, Lafont, Talma et al. 2008). This large study underlines the
positive effects of hypoxia on the articular chondrocyte phenotype and unveils possible new
networks involved in the regulation and maintenance of the HAC phenotype.
It is possible to conclude that hypoxia promotes human articular cartilage function
and tissue integrity via two interconnected pathways: increasing the production of
???????????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????
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FIGURE 1.2.4. The role of HIFs in regulation of the human articular chondrocyte (HAC)
phenotype.
1.3 Myocyte enhancing factor-2 (MEF2) transcription factors
MEF2 members are highly evolutionary conserved genes that belong to MADS DNA-
binding protein family (Potthoff and Olson 2007). First identified by Gossett and colleagues
in the 1989, MEF2 was associated with a DNA-binding activity along the muscle creatine
kinase gene (MCK) in skeletal muscle (Gossett, Kelvin et al. 1989). The single MEF2 gene of
Saccharomyces cerevisiae, Drosophila and Caenorhabditis elegans shows a high
evolutionary conservation with the four MEF2 mammalian genes: A, B, C and D. All these
proteins possess the N-terminal 57 amino acid domain that serves as a DNA-binding domain
(MADS-box), followed by another 26 amino acid domain for high-affinity DNA binding and
dimerisation. The MEF2 dimersisation domain is found only among MEF2 sub-family
members (Molkentin, Li et al. 1996, Black and Olson 1998). The C-terminal domain is
characterised by high sequence variability and shows numerous splice variants (Martin,
Miano et al. 1994) (FIG. 1.3). MEF2 transcription factors recognise a minimal consensus
sequence of YTA (A/T)4 TAR forming an homo/hetero dimer with the other MEF2 proteins
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(Gossett, Kelvin et al. 1989, Andres, Cervera et al. 1995, Molkentin, Li et al. 1996). The
MEF2 members are involved in the control of transcription in diverse developmental and
differentiation circuits and can show overlapping expression in different tissues (Potthoff and
Olson 2007). Furthermore, different studies over recent decades found MEF2 proteins
expressed in lymphocyte, smooth muscle, neural crest, endothelium, and bone with the
highest levels in skeletal muscle and brain where they play a central role in specific cellular
genetic programmes (Lin, Schwarz et al. 1997, Black and Olson 1998, Arnold, Kim et al.
2007, Miller, Swartz et al. 2007, Verzi, Agarwal et al. 2007, Gerstein 2009, Stehling-Sun,
Dade et al. 2009, Agarwal, Verzi et al. 2011). In each of these specific programmes, MEF2
proteins interact with a wide range of co-factors including MyoD, p300, class II HDACs
(4,5,7 and 9), NFAT and GATA, that, in combination with post-translational modifications
such as phosphorylation and sumoylation, regulate a network of activated gene targets.
FIGURE 1.3. Organisation and sequence conservation of the MEF2 gene family. The MADS and
MEF2 domains (N-terminus) show a high degree (%) of amino acidic conservation; conversely the
transcriptional activation domain is variable and is subject to alternative splicing (relative homology
to the human founder MEF2A) (modified from Potthoff and Olson 2007). Note: h – human.
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1.3.1 The core signalling of MEF2 transcription factors
Many signalling pathways interact with the members of the MEF2 family. From yeast
to human, the converging pathway is represented by MAP Kinases, which through
phosphorylation determinates the activation/increase of MEF2 transcriptional activity
(Potthoff and Olson 2007). In particular, it has been demonstrated using that MEF2 members
can be phosphorylated by ERK5 (MAPK7) and p38, increasing their transcriptional activity
(Han, Jiang et al. 1997, Yang, Ornatsky et al. 1998, Hernandez-Torres, Martinez-Fernandez
et al. 2008). A second conserved molecular mechanism involved in the regulation of MEF2
transcriptional activity in mammals is mediated by class II Histone Deacetylases (class II
HDACs). The classical gene-repressing function of class II HDACs is linked with their
ability to remove acetyl groups from the tails of histone proteins and promote chromatin
condensation and transcriptional repression (De Ruijter, Van Gennip et al. 2003). The
protein-protein interaction between the N-terminus of class II HDACs with MADS/MEF2
domain of the MEF2 transcription factors has been demonstrated to silence MEF2 activity on
gene targets (Miska, Karlsson et al. 1999, Borghi, Molinari et al. 2001, Potthoff and Olson
2007). The phosphorylation (by MAPKs and CAMK) of serine residues on N-terminal
domains of HDACs enables the interaction with 14-3-3 chaperon proteins that shuttle the
HDACs to the cytoplasm (McKinsey, Zhang et al. 2000, Chang, Bezprozvannaya et al.
2005). Once HDACs are exported MEF2 proteins become free to interact with other
transcription factors or co-activators such as p300 and activate the expression of target genes
(Vega, Harrison et al. 2004, Vega, Matsuda et al. 2004, Ma, Chan et al. 2005, He, Ye et al.
2011). HDAC translocation is required for MEF2 transcriptional activity but is not sufficient
and additional activating signals such as the direct phosphorylation of MEF2 proteins is
required for their function (Xu, Yu et al. 2002). Furthermore, HDACs and SIRT-1 can
promote the de-acetylation of lysine residues which are the principal acceptors of sumonyl
groups resulting in a repression of MEF2 protein activity (De Ruijter, Van Gennip et al. 2003,
Zhu and Gulick 2004, Gregoire and Yang 2005, Zhao, Sternsdorf et al. 2005, Kang, Gocke et
al. 2006).
1.3.2 MEF2C and chondrocyte biology
Among the four mammalian MEF2 genes, which show overlapping expression in
brain, smooth muscle and skeletal muscle, the C isoform (MEF2C) has recently been found to
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have an important role in bone development (Arnold, Kim et al. 2007, Potthoff and Olson
2007, Dy, Wang et al. 2012).
The human MEF2C gene maps on chromosome 5, at 5q14.3 and spans from
88199923 to 88014059 (185.87 kb, NCBI) on the ‘minus’ chromosomal strand (Krainc, Haas
et al. 1995). Microdeletion, macrodeletion and four de novo heterozygous mutations in the
locus 5q14.3 have been directly linked with severe mental retardation hypothetically caused
by haploinsufficiency of the MEF2C gene (OMIN #613443, mental retardation, autosomal
dominant 20) (Cardoso, Boys et al. 2009, Sobreira, Walsh et al. 2009, Le Meur, Holder-
Espinasse et al. 2010). The human MEF2C gene can produce 21 different mRNAs, 18
alternatively spliced variants and 3 unspliced forms. The alternatively spliced mRNAs differ
by truncation of the 5' end, truncation of the 3' end, or presence or absence of 9-10 cassette
exons(FIG 1.3.2) These mRNAs could potentially code for 16 different mature proteins, 6 of
them truncated (Thierry-Mieg and Thierry-Mieg 2006).
FIGURE 1.3.2 MEF2C mRNA isoforms and protein conding mRNA (A) Schematic
representation of the MEF2C mature mRNA in Homo Sapiens. In red sequence translated in proteins,
in blu processed transcript (no protein), in light green protein coding sequences agreed upon by the
Consensus Coding Sequence project (CCSD) (B)Most of the trascripts give truncated isoforms of the
MEF2C protein (source: ENSMBLE project).
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Zhu and Gulick have shown that MEF2C mRNAs are predominately expressed in
?????????????????????????????????????????????????????????? ??????????????????????????????
amino acid residues that is encoded by the exon 9-10 of MEF2C mRNA. The MEF2C protein
???????? ???? ????????? ???? ?????? ???????????????????????????????? ????????? ????????? ?????
????????????????????????????????????????????????????????????????????????????????????????????
involve the MADS/MEF2 function and the molecular mechanism behind the trans-repression
domain function is not fully understood (FIG. 1.3.2.1).
MEF2 protein isoforms are regulated by another relevant post-transcriptional
modification (Potthoff and Olson 2007). It has been reported that the activity of MEF2C/D
protein is repressed by sumoylation in the C-terminus mediated by HDAC4/SIRT-1
dependent deacetylation of lysine residues (Gregoire and Yang 2005, Zhao, Sternsdorf et al.
2005). In particular, the major acceptor of the sumo-modification in lysine 390(K390), which
???????????????????????????????????????????????? ??????????? ????????????????????? ???????
Gocke et al. 2006). Among several possibilities the authors hypothesised that this domain
could regulate the activation of POL II by MEF2C on target genes (Zhu and Gulick 2004).
FIGURE 1.3.2.1. Schematic of the MEF2C protein phosphorylation and interaction sites.
Phosphorylation on MADS/MEF2 increases the activity of MEF2C transcription factor, and
??????????????????????????????????????????????????????????????????????????????????????????????????
Adapted from Zhu and Gulick 2004 (Molkentin, Li et al. 1996, Han, Jiang et al. 1997, Yang, Ornatsky
et al. 1998, Blaeser, Ho et al. 2000, Vega, Matsuda et al. 2004, Zhu and Gulick 2004, Kang, Gocke et
al. 2006, He, Ye et al. 2011).
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Historically, the MEF2C transcription factor was identified in differentiating
myocytes as a new member of MEF2 family involved in the transcription of the myosin
heavy chain gene (Adolph, Subramaniam et al. 1993, Martin, Schwarz et al. 1993). In mouse
Mef2c mRNA begins to be expressed from the E7.75 in skeletal muscle precursors and is
detectable in brain, skeletal muscle and spleen of adult mice (Edmondson, Lyons et al. 1994).
In skeletal muscle cells MEF2C governs the transcription of basic helix-loop-helix (bHLH)
transcription factors like myogenin and the transcription of muscle genes in collaboration
with other bHLH proteins such as MyoD (the main transcription factor for the determination
of the skeletal muscle phenotype) (Potthoff, Arnold et al. 2007). In addition, MEF2C can
increase the transcription of type II HDACs, such as HDAC 4-9, creating a negative feedback
that regulates MEF2C levels (Haberland, Arnold et al. 2007). Mef2c null mice present an
embryonic lethal phenotype (dying at E9.5) caused by a selective depression of the cardiac
contractile proteins which leads to a failure of cardiac development and elaboration of
vascular defects; whereas Mef2a null mice which can survive until adulthood with only major
vascular and myomitochondrial defects (Lin, Schwarz et al. 1997). Thus, these studies
underline the exclusive role of MEF2C in cardiovascular development (Lin, Schwarz et al.
1997).
Recently, it has been reported that HDAC4 has a pivotal role in the process of
endochondral ossification. Vega and colleagues demonstrated that HDAC4 is expressed in
pre-hypertrophic chondrocytes and, using a Hdac4-/- mouse, that it delays the hypertrophy
stage through direct inhibition of RUNX2 transcriptional activity. (Vega, Matsuda et al.
2004). Subsequently, Arnold and colleagues demonstrated that MEF2C transcription factor is
necessary to drive the correct endochondral ossification process. The inducible Cre/loxP
deletion of the Mef2c gene (by using a Col2a1 promoter in a murine model) prevents the
hypertrophic stage during the last phases of the endochondral ossification process (mice
carrying a transcriptional repressor fused with the Mef2c gene present the same phenotype).
Conversely, the expression of MEF2C-VP16 fusion protein in a murine model results in
premature ossification at E 8.5, which gives a phenotype with excessive ossification of the
ribs and sternum, bone shortening and malformation caused by a premature ossification
(Arnold, Kim et al. 2007). This function is partially due to the direct binding of the Col10
(with SOX9), an important component of the hypertrophic ECM, and RUNX2, a transcription
factor necessary for chondrocyte hypertrophy (Takeda, Bonnamy et al. 2001, Zheng, Zhou et
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al. 2003, Arnold, Kim et al. 2007, Dy, Wang et al. 2012). Interestingly, Arnold and
colleagues observed that the decreased ossification in Mef2c deficient mice was in contrast
with the previously precocious and ectopic ossification of deficient Hdac4 mice observed by
Vega and colleagues. Deletion of one copy of the Mef2c gene in Hdac4-/- mice was sufficient
to rescue the phenotype, and conversely, deletion of one copy of Hdac4 in Mef2c+/- mice (null
Mef2C is embryonic lethal) was sufficient to partially restore the ossification process
(Arnold, Kim et al. 2007). Recently, it has been clarified that Hdac4, after its phosphorylation
and shuttling to the cytoplasm is sequestered by the Salt-inducible kinase 3 (SIK3) in
hypertrophic chondrocytes, via mechanisms that need to be further investigated (Sasagawa,
Takemori et al. 2012).
MEF2C plays a role in diverse tissues coordinating the genetic programmes of the
neural crest, craniofacial, vascular and heart development (Potthoff and Olson 2007).
However, it has also been found to be expressed in adult tissues where it is involved in a
variety of biological process such as the maintenance of skeletal muscle integrity, bone
metabolism, heart hypertrophy, neuronal synapsis and myeloid-lymphoid switching during
haematopoiesis (Akazawa and Komuro 2003, Potthoff, Arnold et al. 2007, Barbosa, Kim et
al. 2008, Stehling-Sun, Dade et al. 2009, Kramer, Baertschi et al. 2012).
Previous work in our laboratory tentatively suggested a role for MEF2C in adult
human articular cartilage. Specifically, in a genome-wide microarray study Lafont and
colleagues identified MEF2C mRNA among those genes that are up-regulated by hypoxia
and down-regulated with the de-differentiation of HACs (through sub-culturing), showing a
similar expression pattern to that of known cartilage-specific genes (Lafont, Talma et al.
2008). The link between MEF2C and ECM biology appears clear during bone development,
but Lin and colleagues highlighted that MEF2C null embryos fail to form endocardial
chambers due to inadequate ECM production (Lin, Schwarz et al. 1997). Furthermore,
MEF2C regulates the expression of Cartilage Link Protein 1 (Crtl1), which is involved in the
correct organisation of the proteoglycan aggregates preventing the degradation by
metalloproteases such as ADAMTS5 in mouse (Rodriguez and Roughley 2006, Lockhart,
Wirrig et al. 2013). In heart development, the expression of MEF2C appears to be regulated
???????????????????????????????????????????????????????????????????????????????????????????
promoter of the murine Mef2c gene (Krishnan, Ahuja et al. 2008). From all of the
aforementioned, we hypothesised that MEF2C may have an important, and as yet
unidentified role in adult cartilage
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1.4 Project aims
The promotion of the differentiated chondrocyte phenotype depends on the activation of
specific genetic programmes which are mainly driven by cartilage master regulator,
transcription factor SOX9. The HAC phenotype is very much adapted to low oxygen levels
(hypoxia) which causes specific changes in the metabolism and gene expression pattern of
HACs. Part of these changes results in the up-regulation of SOX9 gene expression, as a direct
??????? ??? ???????? ???? ??? ???? ??????????? ?????????? ??? ???? ???? ??????????? ????????? ????
adaptation to hypoxia induces many other important changes in the transcription profile of
these cells. In previous studies in our laboratory, we were able to reveal these variations via a
microarray study, which showed that most of the genes relevant for the articular chondrocyte
phenotype were hypoxia inducible (Lafont, Talma et al 2008). Surprisingly, the MEF2C gene
showed the same regulation pattern as SOX9 and COL2A1. Recently, it has been
demonstrated that in a murine model MEF2C is an important transcriptional regulator of
chondrocytes during endochondral ossification (Arnold, Kim et al. 2007). However, its
function in mature articular chondrocytes remains completely unknown. With the aim to shed
light on the transcriptional regulation of the articular chondrocyte phenotype we further
studied the function of MEF2C transcription factor in HACs.
1.4.1 Specific aims
1) Investigate if transcription factor MEF2C is present in intact human articular
cartilage
2) Discover the nature of MEF2C’s hypoxia dependence
3) Uncover the specific role of MEF2C in human articular chondrocytes
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2.1 Materials
2.1.1 Buffers and reagents
Unless otherwise stated, all chemicals were supplied by Sigma-Aldrich (Dorset, UK) or BDH
Chemicals (Dorset, UK). Water was purified using the Ultra-Pure Water System (Ultra Clear
TWF UV plus, SG).
? Phosphate buffered saline (PBS) was obtained as 10x sterile solution (43mM
Na2HPO4, 14mM KH2PO4, 14mM KCL and 1.37M NaCl at pH 7.3) (VWR,
Lutterworth, UK)
Cell culture
? DMEM (Lonza, USA)
? FBS (Gibco, USA)
? Penicillin/streptomycin (Biosera, East Sussex, UK)
? Trypsin-EDTA (Sigma Aldrich company ltd, Dorset, UK)
? ITS (100x) (Sigma Aldrich company ltd, Dorset, UK)
? Opti-MEM I (Invitrogen, USA)
? Lipofectamine 2000 (Invitrogen, USA)
? Collagenase type 2 from Clostridium histolyticum (Worthington, Freehold, NH)
? Actinomycin D EDTA (Sigma Aldrich company ltd, Dorset, UK)
Western Blotting
? Radio-immunoprecipitation assay (RIPA) lysis buffer: 10mM Tris-HCl pH 7.2,
150mM NaCl, 20mM NaF, 5mM EDTA, 1% deoxycholate, 0.1%SDS, 1% Triton
? Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) sample
buffer (4x): 50mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 0.025% bromophenol
blue (prior to use, DTT was added to final concentration 100mM).
? Running buffer for electrophoresis: 25mM Tris-HCl (pH 8.3), 192 mM glycine, 0.1%
SDS (National Diagnostics, USA)
? Transfer buffer: 25mM Trizma Base, 192mM glycine, 20% (v/v) methanol.
? Membrane blocking solution: 5% non-fat dried milk, 0.1% Tween-20 in 1xPBS
? PBST: 1xPBS, 0.1% Tween-20
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? Proteinase inhibitor cocktail (Roche,USA)
? Acrylamide 30% bis-acrylamide 0.8% (Severn Biotech Ltd, UK)
? ECL detection kit (GE Healthcare, UK)
? Polyscreen PVDF Transfer membrane (Perkin Elmer Life Sciences,UK)
? Precision Plus Protein All Blue Standards (Bio-Rad Laboratories, Taiwan)
? DTT (Alexis Corporation, UK)
? Microcystin-LR (Alexis Corporation, UK)
? Methanol (VWR International, UK)
DNA purification
? 1kb DNA Ladder (New England Biolabs,UK)
? 100 bp DNA ladder (New England Biolabs,UK)
? Phenol/Chlorophorm/Isoamylalcohol 25:24:1
RNA purification
? Trizol (Invitrogen)
RT-qPCR
? High Capacity Reverse Transcription kit (Applied Biosystems, cat. no 4368814)
? SYBR® Green PCR Master Mix (Applied Biosystems, cat no 4309155, UK)
? ABI PRISM™ 384-Well Clear Optical Reaction Plate with Barcode (Applied
Biosystems, cat. no 4309849, UK)
? TRIzol (Invitrogen, Carlsbad, CA)
Chromatin Immunoprecipitation Assay (ChIP)
? Lysis buffer: 50 mM Tris–HCl, pH 8.0, 10 mM EDTA, 1% (wt/vol) SDS, protease
inhibitor mix
? RIPA: 10 mM Tris–HCl, pH 7.5, 140 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 1%
(vol/vol) Triton X-100, 0.1% (wt/vol) SDS, 0.1% (wt/vol) Na-deoxycholate
? RIPA ChIP buffer: 10 mM Tris–HCl, pH 7.5, 140 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 1% (vol/vol) Triton X-100, 0.1% (wt/vol) SDS, 0.1% (wt/vol) Na-
deoxycholate, protease inhibitor mix
? TE buffer: 10 mM Tris–HCl, pH 8.0, 10 mM EDTA
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? Elution buffer: 20 mM Tris–HCl, pH 7.5, 5 mM EDTA, 50 mM NaCl
? Complete elution buffer: 20 mM Tris–HCl, pH 7.5, 5 mM EDTA, 50 mM NaCl, 20
????????????????????????????????????????????????????????
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2.1.2 Antibodies and primers
Antibody
specificity
Antibody type Dilution Source Tenique
SOX9
(AB5535)
Polyclonal
Antibody, Rabbit
1:2000 Millipore Western blotting/
immunostaining
EPAS1
(46691)
Monoclonal
Antibody, Mouse
1:250 Santa Cruz Western blotting/
immunostaining
???????
(610958)
Monoclonal
Antibody, Mouse
1:250 BD bioscience Western blotting
MEF2C
(D80C1)
Polyclonal
Antibody, Rabbit
1:500 Cell Signaling Western blotting/
immunostaining/
ChIP
DLX5
(PA519105)
Polyclonal
Antibody, Goat
1:500 Thermo Scientific Western blotting
??????????
(T9026)
Monoclonal
Antibody, Mouse
1:15000 Sigma -Aldrich Western blotting/
immunostaining
Pol II
SC-899 X
Polyclonal
Antibody, Rabbit
3 ug Santa Cruz ChIP
Rabbit IgG
(2729S)
Polyclonal
Antibody
Rabbit
3 ug Cell Signaling ChIP
Alexa Fluor®
488 Goat Anti-
Rabbit IgG
Polyclonal
Antibody, Rabbit
1:2000 Life Science Immunostaining
Alexa Fluor®
594 Goat Anti-
Mouse IgG
Polyclonal
Antibody, mouse
1:2000 Life Science Immunostaining
Mouse Ig HRP
(P0217)
Swine, Ig 1:2000 DAKO Cytomation,
A/S, Denmark
Western blotting
Mouse Ig HRP
(P0218)
Rabbit, Ig 1:2000 DAKO Cytomation,
A/S, Denmark
Western blotting
Table 2.1.2. List of the antibodies
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Table 2.1.2.1. List of primers used for SYBR®green qPCR.
Primers used for human mRNA quantification
Name Sequence
CAIX FWD 5`-TCGGAGCACACTGTGGAAG-3`
CAIX RV 5`-AAGGCCTCGTCAACTCTGG-3`
COL2A1 FWD 5`- GGAAGAGTGGAGACTACTGGATTGAC - 3'
COL2A1 REV 5'- TCCATGTTGCAGAAAACCTTCA - 3'
COL9A1 FWD 5` - GGCTTTCATGATGGAGATCCA – 3`
COL9A1 REV 5` - ATGACCCCTCATGCCTGGTA – 3
COL10A1 FWD 5` - CACGCAGAATCCATCTGAGAATAT-3`
COL10A1 RV 5`-GTTCAGCGTAAAACACTCCATGAA-3`
DLX5 FWD 5` - CTACAACCGCGTCCCAAG– 3`
DLX 5 RV 5` - AACTTTCTTTGGTTTGCCATTC– 3`
HDAC 4 FWD 5`-GGCACGAACCCCCTCAAC-3`
HDAC 4 RV 5`-AGGCGAGCGAGCCTAGAAGT-3`
EPAS1-FWD 5`-AGATGGCCACATGATCTTTCTGT-3`
EPAS1-RV 5`-CCTGTTAGCTCCACCTGTGTAAGTC-3`
HDAC 9 FWD 5`-AGCAAATGGTTTCACAGCA-3`
HDAC 9 RV 5`-AATGTTGGGCAAAGAAGGAG-3`
MEF2C FWD 5`-ACCTATTGCCACTGGCTCAC-3`
MEF2C RV 5`-ACCCATCAGACCACCTGTGT-3`
RPLP0 FWD 5`-CCATTGAAATCCTGAGTGATGTG-3`
RPLP0 RV 5`-CTTCGCTGGCTCCCACTTT-3`
SOX9 FWD 5` - CGCCATCTTCAAGGCGCTGC - 3'
SOX9 REV 5’ - CCTGGGATTGCCCCGAGTGC - 3'
TIMP-1 5`-AGACGGCCTTCTGCAATTC-3`
TIMP-1 5`-TCATAACGCTGGTATAAGGTGGT-3`
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Table 2.1.2.2 Primers binding sites on the MEF2C mRNA isoforms. Primers originate a 100bp
amplicon that overlaps the exon 4 and 5 (A, in light blue the exons junction) which includes the
CCDS sequence and most of the long coding MEF2C mRNA (B).
2.1.3 Principal instruments and software
? 7900HT Fast Real-time PCR system (Applied Biosystems)
? ViiA7 Fast Real-time PCR system(Applied Biosystems)
? Mini-Vertical Unit SE 250 (SDS-PAGE) (GE Healthcare, UK)
? Gel Doc XR (BioRad)
? C1000 TOUCH Thermal Cycler (Biorad)
? Leica™ CM1900UV cryostat
? InVIVO2 400 hypoxic workstation (RUSKINN)
? Ultraview confocal microscope (PerkinElmer)
? Volocity® 3D Image software ( PerkinElmer)
? Graphs and statistical analysis were performed using GraphPad Prism 6.0
Chapter 2 Materials and Methods
51
2.2 Methods
2.2.1 Human articular cartilage tissue preparation and chondrocyte
isolation
Human articular cartilage tissue – preparation for histology
Healthy human articular cartilage was obtained from the femoral condyle and tibial plateau
following amputations due to sarcomas not involving the joint space. Tissue was obtained
following donor’s consent (and in accordance with local ethics committee guidelines).
Virtually full thickness pieces of cartilage were collected on the day of surgery and trimmed
to 0.5-0.7 cm edged pieces before freezing in optimal cutting temperature compound (OCT,
Sakura). Next, 5 μm cryosections were taken from the deepest region to the superficial
region using the Leica™ CM1900UV cryostat.
Human articular chondrocytes
All experiments were performed using human articular chondrocytes (HACs) isolated from
healthy articular cartilage from the knee. Tissue was obtained following donor’s consent
(and in accordance with local ethics committee guidelines) and donor’s age ranged from 8 to
65 years old, including both males and females. For each donors and ID number have been
assigned and listed in Table 2.2.1. Cartilage was collected on the day of surgery and cut into
2-3 mm edged cubes. Next, the cartilage cubes were digested using 1.5mg/ml Collagenase A
(Roche) in 10% FBS/DMEM and incubated for 18 hours at 37ºC with mild shaking.
Following digestion, the chondrocytes were passed through a 100?m cell strainer,
centrifuged at 1500 rpm at room temperature (RT). Viable cells were counted and seeded at
a density of 8 x103 cells/cm2 and cultured for 5-7 days. In the studies performed we used
both P0 (unpassaged) and passaged cells (up to passage P2 - P3).
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Table 2.2.1. List of Donors. The cells used for the experiments presented in this thesis have been
Donors used for the
2.2.2 Hypoxia short time course experiments
The day preceding the experiment, cells were counted and seeded 5 × 103 cells/cm2 in 3.5
cm dishes. HACs (P1-P3) were exposed for 1h, 5h, 10h, and 24h to hypoxia using pre-
equilibrated medium (10% FBS, DMEM) . All experiments were performed in an InVIVO2
400Workstation (Ruskinn Technologies).
2.2.3 Small Interfering RNA (siRNA) transfection
The day preceding transfection, cells were counted and seeded 5 × 103 cells/cm2 in 3.5 cm
dishes. The cells were transfected with siRNA against SOX9 (MWG
ACAGAAUUGUGUUAUGUGAdTdT), MEF2C (s8653, s8654, #143535, Life technologies)
??????? ??????????? ??????????????????????? ?????? ???????? ???????????
CGACAGCUGGAGUAUGAATT) or with negative control sequences (Silencer ® Negative
Control #1 using Lipofectamine™ 2000 (Invitrogen). All siRNAs were used at a final
concentration of 10nM. After 4 hours of incubation in 20% oxygen, OptiMEM-I was
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replaced by previously equilibrated medium (10% FBS, DMEM). Subsequently cells were
incubated at the appropriate oxygen tension (1% or 20%) for the duration of the experiment.
2.2.4 Determination of protein concentration
The protein concentration of each extract was determined using the detergent-compatible
(DC) Protein Assay (Biorad #500-0116) and a UV/vis spectrophotometer (Nanodrop). The
???????????????????????????????????????????????????????????????????????????????????????????????
???????? ???????????? ?????? ??? ??? ??? ??????????? ???????? ??????????????? ?????? ??? ??????????
reagent. After 15 minutes,the absorbance of the colourimetric reaction was measured by
reading the A650. Protein concentrations were estimated by comparison of the absorbance
obtained with a standard curve generated using known concentrations of bovine serum
albumin (BSA).
2.2.5 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Electrophoretic separation of proteins was carried out in a discontinuous stacking/separating
gel system using a Mighty Small II Vertical Electrophoresis apparatus (Hoefer scientific
instruments). A 6% resolving gel and 5% stacking gel were prepared as followed: 30%
acryladmide:bis-acrylamide was mixed with the associated resolving (350mM Tris-HCl (pH
8.8), and 0.1% (w/v) SDS) and stacking (125mM Tris-HCl (pH 6.8), and 0.1 % (w/v) SDS)
gel buffers. Gels were polymerised by adding ammonium persulfate (APS) to 0.04% (w/v)
and tetramethylenediamine (TEMED) to 0.09% (v/v). Prior to electrophoresis samples were
prepared by heating for 5 mins in SDS sample buffer. Prepared samples were loaded onto a
?????????????????????????????????????????????????????????????????????????????????????????????????
(100V/gel) for 1.5 hours. Precision Plus Protein Standards (Bio-Rad) were loaded onto each
gel in order to estimate the size of detected proteins.
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2.2.6 Immunoblotting and immunodetection
Proteins resolved during electrophoresis were transferred to polyvinylidene fluoride (PVDF)
membranes in order to allow detection using appropriate antibodies. Briefly, the hydrophobic
PVDF membrane (Polyscreen® PVDF Transfer Membrane, PerkinElmer Life Siences) was
activated by soaking in 100% methanol and then equilibrated together with the gel in a
transfer buffer. They were placed on top of each other and sandwiched between two sheets of
Whatman®3mm paper and two sponges in a gel holder cassette. The cassette was placed in a
transfer tank containing transfer buffer and proteins were transferred from the gel into the
membrane by electrophoresis at 100V for 1 hour with a cooling system (set to 4 ºC) attached
to the tank in order to prevent the proteins from overheating.
After the transfer, the membranes were taken out and incubated in a blocking solution (PBST
containing 5% fat-free skimmed milk (Tesco, UK) for 1 hour at RT with gentle agitation in
order to block the non-specific binding sites present. Primary antibody was diluted
(usually1:1000) in blocking solution and added to the membranes incubated overnight with
gentle agitation. Membranes were subsequently washed 3 times in PBST; each washing step
was for approximately 5 min. Next, anti-mouse (where appropriate) horseradish peroxidase
(HRP)-conjugated secondary polyclonal antibody was diluted 1:2000 in blocking solution
and applied to the membrane for 1 hour at RT with gentle agitation. Membranes were
subsequently washed 3 times in washing solution, each wash lasting 10 min.
Chemiluminescence was used to detect and visualise the antibodies bound to the targeted
protein. ECL detection western blot reagents (GE Healthcare) and Super RX Film (Fujifilm
????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????
Rad).
2.2.7 mRNA stability assay
HACs were seeded 5 × 103 cells/cm2 in 3.5 cm and incubated for 2 days in hypoxia (1% O2)
and normoxia (20% O2). After 48h hours, the media was switched to media containing 5
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???????????????????????????????????????????????????????????????????????????????????????????
that, total RNA was harvested using TRIzol (Invitrogen) following the manufacturer's
protocol. The mRNA was quantified using RT-q-PCR (standard-curve method see RNA
Extraction, Reverse Transcription, and Real Time PCR section) and half-life was calculated
via GraphPad 6.0 software (one-decay phase equation). All experiments in hypoxia were
performed in a InVIVO2 400Workstation (Ruskinn Technologies).
2.2.8 Immunofluorescence staining
Following fixation, cryosections and cell cultures were blocked with (5% wt/vol BSA, 1%
goat serum wt/vol in 0.01% Tween/PBS) for 1hour at RT, and then incubated for 16 hours
with primary antibody and for 1hour with appropriate secondary antibody. Cells were
??????????????? ????? ???? ??? ?????????????????????????????? ??????? ???? ?? ???? ?????? ????
contained in the mounting agent ProLong® Antifade (Invitrogen). Antibodies used: 1:1000
SOX9 (Millipore, Ab-5535), 1:100 HIF-2? (Santa Cruz, sc-13596), 1:200 MEF2C (Cell
??????????? ?????????????? ????????? ??????? ?????????? ??????? ????????? ????????? ?????
resolution digital images were acquired using a Ultraview confocal microscope
(PerkinElmer) and merged using Volocity® 3D Image software ( PerkinElmer).In order to
test the specificity of MEF2C, SOX9 antibodies have been previously tested on tissue where
has been already proved to be highly expressed (SOX9/mouse articular cartilage,
MEF2C/murine brain) or not detectable (Murine skin) (Figure 2.2.8). Moreover, the
background signal of secondary antibodies has been evaluated in parallel staining of human
articular cartilage section and giving very low background (Figure 2.2.8.1).
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FIGURE 2.2.8. Test in murine tissue of SOX9 and MEF2C antibody. SOX9(C, D) and MEF2C
(A, B) antibodies show specific nuclear staining in murine tissues.
FIGURE 2.2.8.1. Secondary antibody background test. Typical background signal of the Alexa
Fluor® 488 Goat Anti-Rabbit IgG and Alexa Fluor® 594 Goat Anti-Mouse IgG antibodies.
2.2.9 RNA Extraction, Reverse Transcription, and Real Time PCR
RNA was isolated using TRIzol (Invitrogen) with an improvement to the single-step RNA
isolation method developed by Chomczynski and Sacchi (Moniot, Biau et al. 2004). The
concentration and quality of isolated total RNA was measured using the Nano-drop
(ThermoScientific). Complementary DNA (cDNA) was generated using Applied Biosystem’s
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High capacity cDNA Reverse transcription kit with RNAse inhibitors. The reaction was
????????? ?????? ???? ??? ??? ?????? ???? ??? ??? ??? ??? ?????? ??????? ???? ?????????? ??? ????
manufacturer’s instructions. Newly synthesized cDNA was diluted 5 fold in DNase-free
water. For PCR, 4% of the cDNA which was reverse transcribed from 500 ng of total RNA.
Quantitative Real Time PCR (Fast Sybr-Green Master Mix, Applied Biosystems) was
?????????? ??? ?????????? ???? ????????? ??????????? ??????? ??? ????????????? ???????????????
CAIX, COL2A1 and housekeeping gene RPLP0. The qPCR reactions were performed in
triplicates using SYBR Green PCR Master Mix (Applied Biosystem) with appropriate
primers for each gene.
Table 2.2.9. Thermal cycling conditions of the Reverse Transcription.
????? ??? ??? ???? ??? ?? ??? ??
Temperature 25 ºC 37 ºC 85 ºC 4 ºC
2.2.10 Chromatin Immunoprecipitation Assay (ChIP)
Chromatin Immunoprecitpitation assay is an adaptation of the John Arne Dahl and Philippe
Collas`s protocol(Dahl and Collas 2008), and has been optimised for use with 500,000 cells.
For the chromatin immunoprecipitation experiments cells were transfected with specific
siRNA (e.g. MEF2C) and after 1 day of transfection they were cultured for 2 days in hypoxia
or normoxia.
The crosslinking was performed at RT followed by an incubation of 10 minutes with 1%
vol/vol formaldehyde (directly on culture media) and the reaction was quenched for 1 minute
with 125 ml of Glycine (final concentration). The cross-linked cells were washed 3 times
with 5ml of ice-cold PBS/protease inhibitors, and collected using a cell-lifter and
subsequently pelleted by centrifugation (10min, 1000 rpm, 4oC).
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2.2.10.1 Chromatin isolation
After the centrifugation, ice-cold PBS/protease inhibitor supernatant is discarded and the cells
were lysed on ice using 150 μl of Lysis Buffer solution for 5 minutes, and vortexing for 2
times x 5 seconds.
In order to obtain chromatin fragments at an ideal length of circa 500 bp, the cell lysates were
??????????????????????????????????????????????????????????????????????????????????????????
as follows: high power for 8 times 30 seconds with 30 seconds of pause between 2 pulses.
After the sonication, 400μl of RIPA ChIP buffer was added to each sample then 5 seconds of
vigorous vortexing and centrifugation at 13.000 rpm for 10 min. The supernatant (isolated
chromatin) is carefully recovered and transferred in a new 1.5 low-DNA-binding tube.
2.2.10.2 Immunoprecipitation and DNA purification
The day before chromatin isolation 30 ul of Dynabeads Protein A were prepared for each
immunoprecipitation. Briefly, the magnetic beads are washed with ice-cold PBS for 3 times
using a magnetic rack. At the end of the washing procedure, the initial 30 ul of magnetic
beads solution was resuspended in 250 ul of PBS/protease inhibitors and incubated overnight
????????????????????????????????????????????????????????????????????????????????????????????
(magnetic beads/antibody) were captured using a magnetic rack, recovered and released into
isolated chromatin. The tubes containing the complex antibody/bead/chromatin were
?????????? ?????????? ?????? ?? ???????? ??? ?????? ??????? ???? ????? ???? ????
antibody/beads/chromatin were washed with ice-cold PBS/protease inhibitors for 3 x 4
minutes on a rotator 40 rpm. After the last wash the supernatant was removed and 100ul of
TE buffer added and washed for 4 min on a rotator at 40 rpm for the last wash.
The genomic DNA isolation from the complexes magnetic beads/antibody is performed by
??????????????????????????????????????????????????????????????????????????proteinase K) to
???????????????????????????????????????????????????????????????????????????????????????
at 1,200 rpm. The tubeswere removed from the thermomixer and centrifuged for 3 seconds.
The supernatant was recovered and the DNA isolated using Qiagen PCR isolation kit. The
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qPCR reaction (SYBRGreen) was performed on eluted material using primers designed to
specifically amplify a given region of interest
2.2.11 Statistics
All the data were analysed using Prism 6 software (GraphPad), and were typically compared
by a two-tailed paired t-test (Student`s distribution). Results are expressed as mean ± S.E.M.
Probability (P) values less than 0.05 were considered to be statistically significant and have
been denoted: *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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Localisation of
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in intact human articular cartilage
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3.1 Introduction
Articular cartilage (AC) is a layer of hyaline cartilage that covers the ends of bones in
the diarthroidal joints (Nelson, Fairclough et al. 2010). AC is a highly specialized tissue
composed of a mechanically competent matrix which is produced and maintained by a
relatively low number of a sole cell population, namely chondrocytes (Murphy, Thoms et al.
2009). The extracellular matrix (ECM) consists of an abundant amount of collagens that
provide a network in which other large macromolecules, such as proteoglycans, are
connected (Bora and Miller 1987). AC is organized in four distinct zones: the superficial,
middle, deep and calcified cartilage zones. From the superficial to the calcified zone, the
shape and orientation of the chondrocytes are subject to changes: from the superficial
flattened chondrocytes to the spherical chondrocytes of the middle zone. Adult AC presents,
despite a low cell density, a fine regulation between synthesis and degradation of its ECM
(Nelson, Fairclough et al. 2010). The physiology of the human articular chondrocyte (HACs)
is adapted to a hypoxic gradient that has been shown to be a relevant stimulus for promotion
of the HAC phenotype in vitro (Lafont, Talma et al. 2008). The mechanisms that govern the
phenotype-specific gene expression are complex and require networks involving diverse
transcription factors. In their experiments, Lafont et al demonstrated that the expression of
the master regulator SOX9 increased in low oxygen (1%) conditions and is driven by the
??????? ?????????????? ???????? ???????? ???? ?????? ??????? ??? ???????? ??? ????? ???? ???????
function, in HACs little is known about their sub-cellular localisation and persistence in
human AC.
In their studies Henry and colleagues (Henry, Liang et al. 2012) were able to show
that, in murine models, SOX9 maintains the function of master transcription factor for the
ECM genes like CRTL1, COL2A1, COL9 (A1, A2, A3) and COL10A1. The subcellular
distribution of the SOX9 protein appears to be relevant for its function as transcription factor
in a variety of cellular process like: gonad differentiation (Gasca, Canizares et al. 2002),
breast cancer (Chakravarty, Rider et al. 2011) and neuronal crest development (Cheung and
Briscoe 2003). In chondrocytes, the shuttling between nucleus and cytoplasm has been linked
to an increasing of COL2A1 expression and also associated with the phosphorylation in
SER-211 of SOX9 protein (Huang, Zhou et al. 2000).
The myocyte enhancing factor 2 peptide C (MEF2C) plays a pivotal role in the
regulation of genetic stress-response and epigenetic programs of skeletal muscle (Potthoff
?????????????????????????? ???????????????????????????????????????????????????????????????????
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and Olson 2007). Moreover, MEF2C has also been implicated in cell survival, apoptosis,
proliferation and many cellular differentiation genetic programmes. In each of these different
situations, MEF2C exerts its function cooperatively with other transcription factors. In the
context of endochondral ossification, MEF2C drives the expression of chondrocyte
hypertrophy along with SOX9; both transcription factors are involved in the expression of the
hypertrophic ECM marker, COL10A1. In HACs exposed to hypoxia, MEF2C shows a
similar expression pattern to the most established cartilage matrix genes like COL2A1 and
AGN. Nuclear accumulation of MEF2C protein has been associated with an increase of its
transcriptional and epigenetic activity in different cell types in vitro (Borghi, Molinari et al.
2001, Deng, Ewton et al. 2005, Hernandez-Torres, Martinez-Fernandez et al. 2008).
However, there are no studies on MEF2C protein expression and subcellular localisation in
human articular cartilage and HACs.
In this chapter, we report for the first time that chondrocytes in situ in human articular
??????????????????????????????????????????????????????????? ???????????????????????
3.2 MEF2C and SOX9 protein localisation in isolated HACs
Initial experiments were performed to assess if MEF2C and SOX9 proteins were
present in nuclei of passaged HACs and to determine whether hypoxia influences the MEF2C
and SOX9 protein distribution across different sub-cellular compartments
(nucleus/cytoplasm).
To study the MEF2C/SOX9 subcellular localisation passaged HACs were cultured in
LabTek chamber slides for two days under normoxic conditions (20% O2). HACs were
????????? ????? ????? ???????? ?? ????? ????????? ??? ???? ????????? ???? ??????????????? ?????????
(labelled with AlexaFlor®633 staining the cytoskeleton red). Transcription factors are, by
definition, proteins that bind to genomic DNA sequences and control gene transcription via
activation/repression of RNA Polymerase II activity (Fuda, Ardehali et al. 2009). Since the
genomic DNA is contained in the nucleus, the natural location of active transcription factors
would be the nucleus itself. A representative image of a HAC culture (FIG. 3.2) reveals that
MEF2C is present in these cells and, as expected, that the majority of MEF2C protein is
localised within the nucleus, although some low level staining was detected in the cytoplasm
?????????????????????????? ???????????????????????????????????????????????????????????????????
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???????????????????????????????????????????????????????????????????????????????????????????
DAPI (FIG. 3.2 D) staining.
A somewhat different picture was revealed for SOX9 (FIG. 3.2.1 C) which shows a
bipartite distribution between nucleus (FIG. 3.3.1 D) and cytoplasm (FIG. 3.2.1 E). However,
the SOX9 cytoplasmic fraction is not equally distributed across the cytosol itself, but
commonly appears more intense in proximity to the nucleus (a peri-nuclear localisation)
(FIG. 3.2.1).
Finally, we tested if reduced oxygen conditions could have an impact on the MEF2C
and SOX9 protein intracellular distribution. Second passage HACs were cultured in LabTeck
chamber slides for three days under normoxic (20% O2) and hypoxic (1% O2) conditions.
The analysis of confocal images revealed that the distribution of both MEF2C and SOX9 is
not greatly affected by hypoxia (FIG. 3.2.2 and FIG. 3.2.3). There did appear to be more
MEF2C detectable in the cytoplasm in hypoxia, however, nuclear staining was similar in both
oxygen concentrations suggesting that total MEF2C levels may be greater in hypoxic
conditions. However, since immunostaining is not a quantitative technique, and the effect
was not always reproducible, no conclusions were drawn at this stage regarding hypoxia
inducibility of MEF2C.
?????????????????????????? ???????????????????????????????????????????????????????????????????
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FIGURE 3.2. MEF2C protein is present in human articular chondrocytes (HACs). Normoxic
monolayer culture of HACs (from a 53 year old male, N1) stained with DAPI for nuclear localisation
(A, Blue), ????????? (B, Red), MEF2C (C, Green). 32 bit images were merged to create composite
images (D, blue and green; E, red and green; F, red, green and blue). For explanation of the N number
see Table 2.2.1. White bar = 25?m.
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FIGURE 3.2.1. SOX9 protein is present in human articular chondrocytes. Normoxic monolayer
culture of HACs (from a 53 year old male, N1) stained with DAPI for nuclear localisation (A, Blue),
??????????(B, Red), SOX9 (C, Green). 32 bit images were merged to create composite images (D, blue
and green; E, red and green; F, red, green and blue). For explanation of the N number see Table 2.2.1.
White bar = 25?m.
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FIGURE 3.2.2. Subcellular localisation of MEF2C protein in hypoxia. Monolayer culture of
HACs (from a 47 year old male, N3) were cultured for 48 hours in 20% and 1% oxygen. Nuclear
DAPI (A,E Blue), MEF2C (B,F Green), ??????????(D, H, Red). 32 bit images were merged to create
composite images (C, G, blue and green; D, H, red and green). For explanation of the N number see
Table 2.2.1. White bar = 25?m.
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FIGURE 3.2.3. Subcellular localisation of SOX9 protein in hypoxia. Monolayer culture of HACs
(from a 47 year old male, N3) were cultured for 48 hours in 20% and 1% oxygen and stained with
DAPI for nuclear localisation (A, E, Blue), SOX9 (B, F, Green) ??????????(D, H, Red). 32 bit images
were merged to create composite images (C, G, blue and green; D, H, red and green). For explanation
of the N number see Table 2.2.1. White bar = 25?m.
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articular cartilage
We next investigated the localisation of transcription factors SOX9 and MEF2C,
which are largely unreported in articular cartilage. We further investigated whether the
?????? ?????????? ??? ?????? ???? ?????????????? ??????? ??????? ??? ????????????? ?????? ??? ???????
human articular cartilage and not simply in isolated HACs.
Fresh, normal (non-diseased) articular cartilage (obtained from amputations for
sarcomas not involving the joint) were collected on the day of surgery and subsequently cut
into approximately 0.5cm edged cubes and frozen in optimal cutting temperature (OCT)
compound. As previously observed in isolated cells, MEF2C subcellular localisation was
found to be predominately nuclear in human articular cartilage tissue, and is preserved across
the different layers of the tissue. Cryosections derived from 41 and 47 year old male donors
show how chondrocytes in the superficial (FIG. 3.3), mid (FIG. 3.3.1, 3.3.2, 3.3.3) and deep
zone (FIG.3.3.4) of freshly harvested cartilage contain MEF2C protein predominantly in the
nucleus of the cells.
In our laboratory, we have shown that a low oxygen tension is among the most
important pro-chondrocytic stimuli (Lafont, Talma et al. 2008). In previous studies we
???????????????????????????????????????????????????????????????????????????????????????????
transcription factor SOX9 in HAC cultures.
?????????????? ??? ????? ???????? ??? ???????? ???? ???????????? ????????????? ??? ???????
????????? ?????? ???????? ????????? ??? ??????????? ??? ???? ???????? ???????????? ?????? ????????
??????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????
nuclei of the resident chondrocytes in intact articular cartilage across the thickness of the
tissue.
Although SOX9 is essential for cartilage development and maintenance (Bi, Deng et
al. 1999), few are the studies that show SOX9 localisation in human articular cartilage. Our
studies reveal SOX9 protein in cells across the different layers of the cartilage. In addition,
?????????????????????????? ???????????????????????????????????????????????????????????????????
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although, as in isolated HACs it also has an extra-nuclear localisation.
FIGURE 3.3. MEF2C protein is present in human articular cartilage (superficial zone).
Cryosections of human articular cartilage (47 year old male, N3) stained with DAPI for nuclear
localisation (A, Blue),???????????(B, Red), MEF2C (C, Green). 32 bit images were merged to create
composite images (D, red, green and blue; E, red and blue; F, blue and green). For explanation of the
N number see Table 2.2.1. White bar = 25?m.
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FIGURE 3.3.1. MEF2C protein is present in human articular cartilage (mid zone). Cryosections
of human articular cartilage (47 years old male, N3) stained with DAPI for nuclear localisation (A,
Blue), ??????????(B, Red), MEF2C (C, Green). 32 bit images were merged to create composite images
(D, red, green and blue; E, red and blue; F, red and green). For explanation of the N number see Table
2.2.1. White bar = 50?m.
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FIGURE 3.3.2. MEF2C protein is present in human articular cartilage (mid zone). Cryosections
of human articular cartilage (41 years old male, N4) stained with DAPI for nuclear localisation (A,
Blue), MEF2C (B, Green), and merged (C). For explanation of the N number see Table 2.2.1. White
bar = 25?m.
FIGURE 3.3.3. MEF2C protein is present in human articular cartilage (mid zone). Cryosections
of human articular cartilage (41 years old male, N4) stained with DAPI for nuclear localisation (A,
Blue), MEF2C (B, Green), and merged (C). For explanation of the N number see Table 2.2.1. White
bar = 25?m.
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FIGURE 3.3.4. MEF2C protein in human articular cartilage (deep zone). Cryosections of human
articular cartilage (47 years old male, N3) stained with DAPI for nuclear localisation (A, Blue),
MEF2C (B, Green) and ????????? (C, Red). 32 bit images were merged to create composite images
(D, blue and green; E, red and green). For explanation of the N number see Table 2.2.1. White bar =
40?m.
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Cryosections of human articular cartilage (47 years old male, N3) stained with DAPI for nuclear
localisation (A, Blue), ???????(B, Red), and merged (C). For explanation of the N number see Table
2.2.1. White bar = 30?m.
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?????????????? ????????????????????????????????????????????????????????????????????????????
articular cartilage (superficial zone). Cryosections of human articular cartilage (47 years old male,
N3) stained with DAPI for nuclear localisation (A, Blue), ???????(B, Red), MEF2C (C, Green). 32 bit
images were merged to create composite images (D, red, green and blue; E, red and blue; F, green and
blue). For explanation of the N number see Table 2.2.1. White bar = 30?m.
?????????????? ????????????????????????????????????????????????????????????????????????????
articular cartilage (superficial zone). Cryosections of human articular cartilage (47 years old male,
N3) stained with DAPI for nuclear localisation (A, Blue), ???????(B, Red), MEF2C (C, Green). 32 bit
images were merged to create composite images (D, red, green and blue; E, red and blue; F, green and
blue). For explanation of the N number see Table 2.2.1. White bar = 30?m
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?????????????? ????????????????????????????????????????????????????????????????????????????
articular cartilage (superficial/mid zone). Cryosections of human articular cartilage (47 years old
male, N3) stained with DAPI for nuclear localisation (A, Blue), ???????(B, Red), MEF2C (C, Green).
32 bit images were merged to create composite images (D, red, green and blue; E, red and blue; F,
green and blue). For explanation of the N number see Table 2.2.1. White bar = 20?m.
.
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?????????????? ????????????????????????????????????????????????????????????????????????????
articular cartilage (deep zone). Cryosections of human articular cartilage (47 years old male, N3)
stained with DAPI for nuclear localisation (A, Blue), ??????? (B, Red), MEF2C (C, Green). 32 bit
images were merged to create composite images (D, red, green and blue; E, red and blue; F, green and
blue). For explanation of the N number see Table 2.2.1. White bar = 80?m.
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FIGURE 3.3.10. SOX9 protein in human articular cartilage (superficial zone). Cryosections of
human articular cartilage (41 years old male, N4) stained with DAPI for nuclear localisation (A,
Blue), SOX9 (B, green), and merged (C). For explanation of the N number see Table 2.2.1. White bar
= 50?m.
FIGURE 3.3.11. SOX9 protein in human articular cartilage (mid zone). Cryosections of human
articular cartilage (41 years old male, N4) stained with DAPI for nuclear localisation (A, Blue), SOX9
(B, green), and merged (C). For explanation of the N number see Table 2.2.1. White bar = 50?m.
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???????????????????????????????????????????????????????????????????????????????????????????
articular cartilage (mid zone). Cryosections of human articular cartilage (47 years old male, N3)
stained with DAPI for nuclear localisation (A, Blue), ???????(B, Red), and SOX9 (C, Green). 32 bit
images were merged to create composite images (D, red, green and blue; E, red and blue; F, green and
blue). For explanation of the N number see Table 2.2.1. White bar = 50?m.
???????????????????????????????????????????????????????????????????????????????????????????
articular cartilage (mid zone). Cryosections of human articular cartilage (47 years old male, N3)
stained with DAPI for nuclear localisation (A, Blue), SOX9 (B, green). ??????? (C, Red). 32 bit
images were merged to create composite images (D, blue and green; E, blue and red; F, red, green and
blue). For explanation of the N number see Table 2.2.1. White bar = 50?m.
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???????????????????????????????????????????????????????????????????????????????????????????
articular cartilage (deep zone). Cryosections of human articular cartilage (47 years old male, N3)
stained with DAPI for nuclear localisation (A, Blue), ???????(B, Red) and SOX9 (C, green). 32 bit
images were merged to create composite images (D, red, green and blue; E, blue and red; F, blue and
green). For explanation of the N number see Table 2.2.1. White bar = 80?m.
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3.4 Discussion
Healthy human articular cartilage is a rare and precious specimen for laboratory
investigation and scarcity of samples is the main reason for the low number of
immunolocalisation studies using this tissue. Consequently there is a very limited amount of
????????????????????????????????????? ????????????????????????????????????????????? ???????
knowledge none on MEF2C localisation in human cartilage.
Human articular cartilage is an avascular and aneural tissue and it experiences low
levels of oxygen; but no studies have measured directly, in human knees, the percentage of
oxygen present in the superficial, middle and deep zone of the human articular cartilage
(Lundoles.K 1970, Brighton and Heppenstall 1971, Silver 1975). At the transcriptional level,
??????????????????????????????????????????????????????????????????????????????????????????????
from the proteasome degradation and start the genetic response to hypoxia (Semenza 2001).
??????????? ???? ????????? ??? ???? ?????? ????????? ?????? ??? ?????? ??? ??????? ????????? ??? ???
activated hypoxia response and indirect evidence of experienced hypoxia in the original
??????????? ????????????? ?? ????????? ?????? ???? ????????? ??????? ??????????? ???
macroscopically undamaged sites of osteoarthritis cartilage (Yang, Kim et al. 2010); however
such tissue could harbour pathological changes at the cell and molecular level. Our data,
being derived from healthy cartilage, immediately processed, does not suffer from such
????????????? ??? ????? ?????????? ???????? ?? ?????? ???? ????????? ???????? ????????? ???????????? ???
expressed in adult human articular cartilage, and furthermore, co-localises with its genetic
target SOX9 in the nuclei of the resident chondrocytes throughout the thickness of the tissue.
The activity of transcription factors, such as SOX9, is extensively regulated by post-
translational modifications. The nuclear import of SOX9 in particular, and SOX proteins in
general, is likely to play a pivotal role in the activation of their target genes (Huang, Zhou et
al. 2000, Huang, Chung et al. 2001, Preiss, Argentaro et al. 2001, Chikuda, Kugimiya et al.
2004, Haudenschild, Chen et al. 2010). SOX9 protein has three Serine residues Ser64 -181-211 ,
which have been directly associated with increased transcriptional activity and but just the
phosphorylation of Ser211 with nuclear import of SOX9 in chondrocytes (Huang, Zhou et al.
2000, Huang, Chung et al. 2001, Nakamura, ). In contrast to murine chondrocytes of the
growth plate, SOX9 protein in the fully differentiated adult human articular chondrocytes
does not show an exclusive nuclear localisation but is also present in the cytosol of
chondrocytes throughout the articular cartilage thickness. Further studies would be required
?????????????????????????? ???????????????????????????????????????????????????????????????????
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to investigate the effect of hypoxia on the protein distribution of SOX9, e.g. by possible
regulation of protein shuttling.
MEF2C transcription factor is known to be involved in muscle and cardiovascular
development (Potthoff and Olson 2007) and it has recently been shown to play a key role in
chondrocyte hypertrophy co-ordinately with SOX9 (Dy, Wang et al. 2012). In a previous
microarray analysis, we found that MEF2C was upregulated during hypoxia-induced re-
dedifferentiation of HACs (Lafont, Talma et al. 2008). In this study, MEF2C protein has been
identified for the first time in normal human articular cartilage, and shows a predominantly
???????? ????????????? ?????? ??? ????????????? ????? ???? ?????????? ??? ????????????? ??? ??? ?????
present, to varying degrees in the cytoplasm. The enhancement of the MEF2C staining
observed in isolated chondrocytes cultured in hypoxia could be a consequence of increased
MEF2C protein expression. The function and the regulation of MEF2C protein are further
explored and discussed in subsequent chapters.
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4.1 Introduction
Since AC is an avascular tissue, hypoxia has been proposed as a potential regulator of
chondrocyte development and function (Maes, Carmeliet et al. 2012). Studies in murine
embryonic development suggest that low oxygen tension is vital, not only for chondrogenic
differentiation, but also for chondrocyte proliferation and survival (Schipani, Ryan et al.
2001, Hirao, Tamai et al. 2006, Murphy, Thoms et al. 2009). In human AC, strategies have
been developed by the resident cells (chondrocytes) to respond to the chronic hypoxia
experienced such as increased expression of tissue-specific Extra Cellular Matrix (ECM)
genes and inhibition of angiogenesis (Murphy, Thoms et al. 2009). The most important
intracellular molecular mechanism for biological responses to hypoxia is the Hypoxia
???????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????
?????????? ???? ????????? ??? ?????????? ???????? ???????????? ?????? ??????? ??? ???????????????
involved in regulating the response to chronic hypoxia. This is an interesting aspect,
?????????????????????????????????????????????????????????????????????????????????????????
the differentiated phenotype by up-regulating the essential transcription factor SOX9 (Lafont,
Talma et al. 2008). Hypoxia is also responsible in for various other important changes in gene
expression in HACs. A microarray study published by our laboratory has identified many
genes potentially relevant for the expression of the differentiated chondrocyte phenotype
which were also hypoxia inducible (Lafont, Talma et al. 2008) - among them was Myocyte
Enhancing Factor 2C (MEF2C).
MEF2C gene expression is driven by tissue-specific transcription factors (Potthoff
and Olson 2007) and its regulation has been mostly studied in murine muscle, brain and heart
development. During heart development low oxygenation increases the transcriptional
????????? ??? ???????? ?????? ?????????? ?????? ????? ??????????? ???? ????????????? ????
transcription of a sarcomere protein TITIN (Krishnan, Ahuja et al. 2008). However, there is
little experimental evidence about the hypoxic regulation of MEF2C gene expression in
human adult tissues.
In this chapter are detailed investigations of MEF2C regulation, which we
???????????????????????????????????????????????????????????????????????????????????
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4.2 MEF2C is upregulated by hypoxia
In order to confirm if MEF2C mRNA and protein are hypoxia-inducible, passaged
HACs from 7 different donors (8-65 years old, average 25.5 years , 2 females and 5 males)
have been cultured in normoxia (20% O2) and hypoxia (1% O2) for 48 hours. MEF2C mRNA
transcripts have been quantified at the same time as SOX9 and the key SOX9 target gene
COL2A1 which encoded for the major component of cartilage. MEF2C mRNA levels were
significantly increased by hypoxia treatment and followed the same pattern as SOX9 and
COL2A1 expression (FIG. 4.2).
Western blotting with a MEF2C antibody revealed different bands. In order to
investigate MEF2C specificity of these bands, we silenced via siRNA all the MEF2C mRNA
variants (see materials and methods) in HACs and cultured for a further 48 hours in hypoxia
or normoxia. This confirmed the specificity of our antibody as the bands were not present in
the MEF2C-depleted samples. Furthermore, MEF2C protein detection in HACs was
increased in hypoxia (in agreement with mRNA data) (FIG. 4.2.1 A, B, C).
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FIGURE 4.2. MEF2C gene expression is significantly upregulated by hypoxia in HACs. HACs
(passage 1 or 2 monolayer cultures) were incubated for 2 days in 20% or 1% oxygen tension. MEF2C,
SOX9 and COL2A1 mRNA levels were quantified using RT-qPCR and expressed relative to 20%
oxygen levels. Gene expression was normalised to RPLP0. Data show the average (±S.E.M.) gene
expression levels measured in 7 independent experiments (icells from 7 unique donors, patients N 2,
6, 9, 10, 23, 24, 28). Note: **P < 0.01. For explanation of the N number see Table 2.2.1.
FIGURE 4.2.1. Hypoxia increases MEF2C protein levels in HACs. Western Blot showing an
increase in MEF2C protein level in HACs after 2 days in hypoxia (1% oxygen, patient N5) (A).
MEF2C protein isoforms were identified as those bands depleted by MEF2C-specific siRNAs (B,
patient N6 ) and (C, patient N7). All experiments were performed using passage 1-2 cells. Note: CTR
- control siRNA, siMEF2C- pre-validated MEF2C targeting oligos; ?-TUB – ?-tubulin. For
explanation of the N number see Table 2.2.1.
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????????????????? ???????????????? ????? ??????????????????????????
hypoxia
In order to understand the mechanism behind the hypoxic regulation of MEF2C, we
?????? ????????????? ???? ????????? ???? ???????????? ??????? ????????? ????? ????? ????????? ???
hypoxia and normoxia for 48 hours. Significant depletion of HIF-1? was achieved as
determined by western blotting (FIG. 4.3 A) and significant reduction in a known HIF-1?
target gene CAIX indicated a functional knockdown (FIG. 4.3. B). HIF-1? depletion did not,
however, affect the levels of MEF2C protein (FIG. 4.3 A) of mRNA (FIG. 4.3 C).
We next investigated HIF-2? - the other major HIF isoform. A previously optimised
HIF-2? (gene name -EPAS1) silencing protocol was used to deplete EPAS1 transcripts in
HACs derived from the articular cartilage of 9 different donors (from a range of 11-62 years
old, average 33 years, 3 females and 6 males). Western blotting and RT-qPCR showed that
the EPAS1 transcript (>80%) and protein were efficiently silenced (FIG. 4.3.1, FIG. 4.3.2).
Quantification of MEF2C mRNA levels reveals a significant decrease of 44% (on average) in
hypoxia in HIF-2? depleted cells, while MEF2C protein levels were likewise reduced in
hypoxia (FIG. 4.3.2A). In line with our previous reports (Lafont, Talma et al. 2008) hypoxic
induction of SOX9 mRNA levels (FIG. 4.3.1) and protein levels (FIG. 4.3.2) was HIF-2?
dependent.
????????? ??????????????????? ??????????? ???? ????????????????????????????????????
????????????????????????????? ?????????????????????????????????????????????????????????????
to hypoxia and is able to regulate gene expression via different modalities, from the
transcriptional cascade (e.g. expression of other transcription factors) to post-transcriptional
???????????? ??? ?????? ??? ???????? ????????????????????? ????? ????????? ????? ???????????????
need to study the potential role of effects such as mRNA stability or indirect upregulation
mediated by other hypoxia inducible genes.
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??????????? ????????????????????????? ?????????????????? ??????????? ??????????? (A) HACs
????????? ?? ??? ???????????? ??????????????? ???????????????????????? ?????????? ??????? ??????????? ????
cultured for 2 days in hypoxia (1% O2). Western blots revealed no change in MEF2C protein levels in
??????????????????????????????????????????? ?????????????????????????????????????????????? ????????
expression levels measured in 4 independent experiments (i.e. cells from 4 unique donors). RT-qPCR
revealed an almost total inhibition of expression of known HIF target gene CAIX in HIF-1? depleted
cultures (B), however, no significant effect was observed on MEF2C mRNA expression (C). Note:
siCTR – control siRNA; ?-TUB – ?-tubulin; ****P < 0.0001. For explanation of the N number see
Table 2.2.1.
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FIGURE 4.3.1. HIF-2? depletion decreases MEF2C mRNA expression levels in hypoxia. HACs
(passage 1 or 2 monolayer cultures) were transfected with EPAS1 (which encodes HIF-2?) targeting
oligos (siEPAS1) and incubated for 2 days in 20% or 1% oxygen tension. EPAS1, MEF2C, SOX9 and
COL2A1mRNA levels were quantified using RT-qPCR and expressed relative to 20% oxygen levels.
Gene expression was normalised to RPLP0. Data show the expression average (±S.E.M.) measured in
9 independent experiments (i.e. cells from 9 different donors, N 7, 8, 9, 10, 12, 14, 29, 30, 31). Note:
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; CTR – control siRNA; siEPAS1 – EPAS1
targeting siRNA. For explanation of the N number see Table 2.2.1.
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FIGURE 4.3.2. HIF-2? depletion decreases MEF2C protein levels in hypoxia. HACs (passage 1
or 2 monolayer cultures) were transfected with EPAS1 targeting oligos (siEPAS1) and cultured for 2
days in hypoxia (1% oxygen). Western blots showing a decrease in HIF-2?, MEF2C and SOX9
protein levels in EPAS1 (which encodes HIF-2?) depleted cultures (A). RT-qPCR was used to assess
the silencing efficiency in parallel cultures from each donor (B). Note: siCTR – control siRNA;; ?-
TUB – ?-tubulin. For explanation of the N number see Table 2.2.1.
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4.4 Depletion of SOX9 decreases MEF2C protein levels and its steady-state
mRNA levels
In order to investigate a possible role for SOX9 in regulation of MEF2C expression,
we depleted SOX9 using a protocol previously established in our laboratory. Passaged HACs
from 8 different donors (from a range of 13-68 years old, average 46.2 years, 3 females and 5
males) were transfected with gene specific siRNA against SOX9, cultured in 20% O2 and
subsequently moved to hypoxia for 48 hours. We used western blotting and RT-qPCR to
assess the silencing efficiency, which confirmed the depletion of the SOX9 protein and
mRNA (FIG. 4.4 and FIG. 4.4.1).
Under both hypoxic and normoxic conditions, the ablation of SOX9 leads to a
significant decrease of MEF2C mRNA and protein levels (FIG. 4.4 and FIG. 4.4.1).
Significant reduction of SOX9 target gene COL2A1 further confirmed a functional SOX9
???????????????????????????????????????????????????????????????????????????????????????
stabilisation indicating that the effect on MEF2C is not due to HIF-2? per se (FIG. 4.4.2).
****
*
* ** *
**
******
FIGURE 4.4. SOX9 depletion decreases MEF2C gene expression levels in normoxia and
hypoxia. HACs (passage 1 or 2 monolayer cultures) were transfected with SOX9 targeting oligos
(siSOX9) and cultured for 2 days in normoxia (20% O2) or hypoxia (1% O2). SOX9, MEF2C and
COL2A1mRNA levels were quantified using RT-qPCR., and expressed relative to 20% O2 levels.
Gene expression was normalised to RPLP0. Data show the expression average (±S.E.M.) measured in
6-8 independent experiments (i.e. cells from 6-8 different donors; N 13, 12 13, 14, 24, 29, 30). Note:
*P < 0.05, **P < 0.01, ****P < 0.0001; siCTR – control siRNA. For explanation of the N number see
Table 2.2.1.
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FIGURE 4.4.1. SOX9 depletion decreases MEF2C protein levels. HACs (passage 1 or 2
monolayer cultures) were transfected with SOX9 targeting oligos (siSOX9) and cultured for 2 days in
hypoxia (1% O2) or normoxia (20% O2). Western blotting showed a consistent decrease in MEF2C
protein levels in SOX9 depleted cultures. Note: siCTR – control siRNA; ?-TUB – ?-tubulin. For
explanation of the N number see Table 2.2.1.
SOX9
HIF2
MEF2C
-TUB
siC
TR
1%O2
N15
siS
OX
9
??????? ??????? ????? ?????????? ?????????? ?????? ???????? ??????? ???????? ?????????? ???????
levels. HACs (passage 1 or 2 monolayer cultures) were transfected with SOX9 targeting oligos
(SOX9) and cultured for 2 days in hypoxia (1% O2) or normoxia (20% O2). Western blotting showed
a decrease in MEF2C protein levels in response to SOX9 depletion, without a change in HIF-2?
levels. Note: siCTR – control siRNA; ?-TUB – ?-tubulin. For explanation of the N number see Table
2.2.1.
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4.5 Hypoxia does not alter MEF2C mRNA half-life
Gene expression is a multilayered process and can be regulated at transcriptional,
post-transcriptional and translational levels. With regard to hypoxia related gene expression,
in addition to directly regulating gene expression via direct binding of HRE sequences on a
specific gene, the HIF transcription factors could indirectly modulate the expression of target
genes through microRNAs or other protein involved in controlling mRNA stability. In order
to further probe the mechanism of action of MEF2C mRNA upregulation by hypoxia, we
examined the half-life of the MEF2C transcripts in HACs treated with an inhibitor of
transcription, Actinomycin-D under both normoxic and hypoxic conditions.
HACs from 2 donors (an experiment done in duplicate) were cultured for 48 hours in
20% O2 and 1% O2, treated with 5uM Actinomycin-D (Sigma) and cells were harvested after
1h, 2h, 3h, and 4h. We monitored the amount of non-degraded MEF2C mRNA by analysing
equal amounts of total mRNA with RT-qPCR using RPLP0 as internal control. Using linear
regression analysis (in Graph-Pad 6.0 software) we identified the line that best fits the data
and a decay rate constant is obtained from the slope of a semi-logarithmic plot of MEF2C
mRNA concentration as a function of time (FIG. 4.5 B). Subsequently, the decay rate has
been used to determine the mRNA half-life. The analysis of the half-life of MEF2C mRNA
revealed no difference between that measured in normoxia and hypoxia despite the higher
starting quantity (steady-state levels) of MEFC mRNA in hypoxia (FIG. 4.5 A).
Importantly, these experiments revealed that the increase of MEF2C mRNA in
hypoxia does not involve alterations in its mRNA stability and therefore may be due to a
transcriptional mechanism.
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FIGURE 4.5. Hypoxia does not affect MEF2C mRNA decay rate in HACs. Confluent (passage 1)
HAC monolayer cultures were maintained for 1 day in normoxia (20% O2) or hypoxia (1% O2) (A)
before treatment with 5uM Actinomycin D (B). Samples were harvested after 1, 2, 3 and 4 hours.
SOX9 levels were quantified using RT-qPCR and expressed relative to 0 hours. Gene expression was
normalised to RPLP0. Data show the average (±S.E.M.) measured in 4 independent experiments (i.e.
cells from 2 different donors; N16, 32). MEF2C mRNA decay curves showed no significant
difference between normoxic and hypoxic conditions. Note: *P < 0.05. For explanation of the N
number see Table 2.2.1.
4.6 MEF2C and SOX9 mRNA levels show an early up-regulation pattern in
hypoxia time course experiments
HACs from 6 different donors (from a range of 16-58 years old, average age 32.8
years, 3 females and 3 males) were seeded at 150,000 cells per 3.5 cm dish the day before the
experiment and cultured in the InVIVO2 400 workstation (1% O2, 37° C) with pre-equilibrated
media. The use of the InVIVO2 400 workstation allows us to work in a controlled hypoxic
environment reducing the variability due to the inevitable handling in normoxia in a normal
tissue culture cabinet. After 1, 5, 10 and 24 hours of hypoxia, HACs were harvested and RT -
qPCR was used to assess gene expression. The quantification of the mRNA expression
reveals that genes previously identified as hypoxia inducible have different kinetics of
regulation in HACs. In fact, SOX9 mRNA shows the quickest response to hypoxia, (being
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significantly upregulated after only 5 hours of hypoxia treatment) whereas H19, COL2A1,
CAIX genes showed a somewhat slower response (FIG. 4.6). Qualitatively, MEF2C hypoxic
induction shows a high similarity to SOX9, but, due to the large variability between donors,
is not statistically significant until 24 hours of hypoxic treatment (FIG. 4.6)
We next investigated the expression of SOX9, MEF2C, COL2A1, CAIX mRNA at
even earlier time points up to 5 hours (0.5, 1, 2.5 and 5 hours). HACs from 4 different donors
(from an age range of 16-58 years old, average 32.8 years, 2 females and 2 males) were
seeded at 150,000cells per 3.5 cm2 dish the day before the experiment and cultured in the
InVIVO2 400 workstation (1% O2, 37° C) with pre-equilibrated media. RT-qPCR analysis
again revealed that SOX9 is an early hypoxia responsive gene in HACs (FIG. 4.6.1).
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FIGURE 4.6. Gene expression in HACs - hypoxia time course. HACs (passage 1 or 2 monolayer
cultures) were incubated for 1, 5, 10, 24 hours in 20% or 1% O2 tension. SOX9, MEF2C, COL2A,
H19, CAIX and FIH mRNA levels were quantified using RT-qPCR and expressed relative to 1h
timepoint in 20% O2 levels. Gene expression was normalised to RPLP0. Data show the expression
average (±S.E.M.) measured in 6 independent experiments (i.e. cells from 6 different donors; N 1, 9,
16, 29, 32, 33). Note: *P < 0.05, **P < 0.01. For explanation of the N number see Table 2.2.1.
** **
*
*
*
*
*
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FIGURE 4.6.1. SOX9, MEF2C, COL2A1, CAIX gene expression - hypoxia time course (0.5, 1,
2.5, 5 hours) HACs (passage 1 or 2 monolayer cultures) were incubated for 0.5, 1, 2.5, 5 hours in 1%
O2. SOX9, MEF2C, COL2A, CAIX were quantified using RT-qPCR and expressed relative to 0.5h in
20% O2 levels. Gene expression was normalised to RPLP0. Data show the expression average
(±S.E.M.) measured in 4 independent experiments (i.e. cells from 3 different donors: N18, 19, 22).
Note: *P < 0.05; 1% - 1% O2; 20% - 20% O2. For explanation of the N number see Table 2.2.1.
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???? ???????????????? ???????????????????????????????????????????
hypoxia
We next studied the protein up-regulation in short term hypoxia experiments. In
previous work in our laboratory SOX9 protein regulation was extensively studied in HACs
(Lafont, Talma et al. 2008). However, the early expression profile of these proteins is largely
unknown. With regard to hypoxic up-regulation of MEF2C protein no data on any cell type
are available in the scientific literature.
Passaged HACs were seeded at 150,000 cells per 3.5 cm dish the day before the
experiment and cultured in the InVIVO2 400 workstation (1% O2, 37oC) with pre-equilibrated
media. After 1, 5, 10 and 24 hours of hypoxia, HACs were harvested and lysed in RIPA
????????????????????????????????????????????????????????????????????????????????????????????
degraded; while in hypoxia the protein escapes degradation. Hence, HIF responses to hypoxia
are most rapid as they involve post-translation regulation. In addition, we have shown by the
work involved in this project that hypoxic induction of MEF2C gene expression is HIF-2?
dependent. Therefore, we first investigated HIF-2? protein induction in hypoxic at early time
???????? ???????? ????????? ??? ?????? ????????? ??????? ???????? ????? ??????? ???????? ??? ??????????
stabilized by 1 hour of hypoxic treatment (FIG. 4.7). Subsequently, yet shorter time course
????????????????????????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????
HACs were treated for 1, 2.5, 5 and 24 hours with the hypoxia mimetic and 2-oxoglutarate
???????????????????????????????????????????????????????????????????????????????????
(FIG. 4.7.2).
Perhaps not surprisingly, the temporal course of hypoxic induction of SOX9 protein
was more variable than HIF-2?. In fact, western blotting of passaged HACs exposed for 1, 5,
10 and 24 hours to hypoxia shows that the SOX9 proteins were increased after 1 hour (FIG.
4.7.3 A) 5 hours (FIG. 4.7.3 B) or 10 hours (FIG. 4.7.3 C) of hypoxia treatment. Early time
point experiments (FIG. 4.7.4) and DMOG treatment experiments (FIG. 4.7.5), have shown
that it was most consistently upregulated by 5 hours. However, the DMOG experiments show
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a better reproducibility at these shorter time points. This may be due to a more complete or
??????????????????????????????????
Finally we assessed the effects on MEF2C protein levels of short hypoxia exposure,
revealing, somewhat similarly to SOX9, an early induction within 5 hour of hypoxic
treatment (FIG. 4.7.6). However, further experiments are needed to more accurately
determine the dynamics of MEF2C protein up-regulation in hypoxia.
??????????????????????????? ??????????? ??????? ?????????? ?? ????????? HACs (passage 1 and 2)
were incubated for 1, 5, 10, 24 hours (A, B) and 1, 5, 24 hours (C) in 20% or 1% O2?????????????????
(indicated by the black arrow) was already detectable by 1h of hypoxia incubation Note: ?-TUB – ?-
tubulin; h – hours. For explanation of the N number see Table 2.2.1.
.
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??????????????????????????????????????????????????????????????????? ????????? HACs (passage 1
and 2) were incubated for 0.5, 1, 2.5 and 5 hours in 1% O2???????????????????????????????????????????
arrow. Note:; ?-TUB – ?-tubulin. For explanation of the N number see Table 2.2.1.
????????????????????????????????????????????????? ????????? HACs (passage 1 and 2) were
incubated for 1, 5, and 24 hours in 50uM or 500uM DMOG or control vehicle (A), or for 1, 2.5, and 5
??????????? ?????????????????????????????????????????????????????????????????????????????????????????
hour of DMOG treatment. Note: CTR - vehicle;; ?-TUB - ?-tubulin; h - hours.
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FIGURE 4.7.3. SOX9 protein expression – hypoxia time course. HACs (passage 1 and 2) were
incubated for 1, 5, 10, 24 hours in 20% or 1% O2 showing SOX9 protein upregulated by hypoxia at
different time points:1 hour (A), 5 hours (B), and 10 hours (C). Note: ?-TUB - ?-tubulin; h - hours.
For explanation of the N number see Table 2.2.1.
Chapter 4 Regulation of MEF2C expression in human articular chondrocytes
101
0.5h 5h 0. 5h 1h 2.5h 5h
20%O2 1%O2
SOX9
-TUB
0.5h 5h 0. 5h 1h 2.5h 5h
20%O2 1%O2
SOX9
-TUB
0.5h 5h 0. 5h 1h 2.5h 5h
20%O2 1%O2
SOX9
-TUB
N19
N22
N22
FIGURE 4.7.4. SOX9 protein expression in response to short-term hypoxia. HACs (passage 1
and 2) were incubated for 0.5, 1, 2.5, and 5 hours in 1% O2. SOX9 protein was upregulated by 5 hours
of hypoxia incubation (A, B, C) Note: CTR - vehicle; ?-TUB - ?-tubulin; h - hours. For explanation
of the N number see Table 2.2.1.
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FIGURE 4.7.5. SOX9 protein expression - DMOG time course. HACs (passage 1 and 2) were
incubated for 1, 5, and 24 hours in GM (Growth Media), CTR 1 (0.3% of vehicle-DMSO) and CTR 2
(0.03% of vehicle-DMSO) of the vehicle (A) and 50uM, 500uM of DMOG (B), 1, 2.5, 5 hours (C) of
DMOG. Western blottings showed SOX9 protein already upregulated by 5 hours of DMOG
treatment. Note: ?-TUB - ?-tubulin; h – hours. For explanation of the N number see Table 2.2.1.
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FIGURE 4.7.6. MEF2C protein expression is increased by 5 hours of hypoxic treatment. HACs
(passage 1 and 2) were incubated for 5, 10 and 24 hours in 20% or 1% O2. MEF2C protein was up-
regulated after 5 hours of hypoxia incubation. Note: ?-TUB – ?-tubulin; h-hours. For explanation of
the N number see Table 2.2.1.
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4.8 Discussion
Hypoxia is often associated with pathologies like ischemia and tumour growth (Harris
2002, Kaelin and Ratcliffe 2008). However, hypoxia adaptation is vital for a variety of
normal physiological processes such as embryonic development and can be found in
specialized microenvironments in adult tissues (Simon and Keith 2008). Historically,
different tissues have been found to be adapted to hypoxia, for example kidney medulla, bone
marrow and more recently human articular cartilage (Kaelin and Ratcliffe 2008, Murphy
2011). At the molecular level, the response to lower oxygen levels may be maintained by
various mechanisms including the mTOR pathway, the endoplasmic reticulum (ER) stress
response and the HIF pathway (Lendahl, Lee et al. 2009). In our laboratory it has been found
????????????????????????????? ?????????????????????????? ????????????????? ????????????????????
chondrocyte phenotype. Hypoxia causes global changes to the transcription profile of HACs
(Lafont, Talma et al. 2007). In a previous microarray study performed in our lab we
discovered that many genes intimately associated with the chondrocyte phenotype such as
SOX9 and the cartilage ECM encoding genes were themselves hypoxia-inducible (Lafont,
Talma et al. 2008). Interestingly, among them was MEF2C, a transcription factor involved in
numerous differentiation programmes but whose expression had not been described as
correlated with hypoxia in human adult tissues.
The results of this chapter reveal insights into the regulation of MEF2C gene
expression by hypoxia. In particular (1) hypoxia induces MEF2C expression in a HIF-
2?/SOX9 dependent manner in HACs. (2) Hypoxia induces up-regulation of MEF2C gene
expression without affecting its mRNA half-life, thus indicating a transcriptional activation
mechanism of induction (3) MEF2C mRNA and protein levels, like SOX9, are rapidly
increased in response to hypoxia.
?????? ??????????????? ????????????????????? ?????????????????????
manner in HACs
MEF2 family protein members have a unique ancestor gene - MADS (MCM1,
agamous, deficient, SRF). Vertebrates possess 4 MEF2C genes A, B, C, D (Potthoff and
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Olson 2007). In embryonic tissues the activation of MEF2 gene transcription is associated
with the activation of differentiation programmes in muscle, neuronal and bone tissue
showing overlapping expression. In adults MEF2 transcription has been associated with
synapse remodelling, smooth muscle maintenance and pathologies such as cardiac
hypertrophy (Akazawa and Komuro 2003, Potthoff, Arnold et al. 2007, Potthoff and Olson
2007, Barbosa, Kim et al. 2008). MEF2 proteins are expressed principally in muscle and
brain tissues but some reports claim MEF2 proteins to be ubiquitous, including MEF2A,
which is expressed in both muscle and non-muscle cells (Potthoff and Olson 2007). The
regulation of MEF2C gene expression is driven by cell-specific transcription factors such as
myogenic bHLH proteins (muscle) or endothelin (neuronal crest) or by pathways like ERK5
(Yang, Ornatsky et al. 1998, Dodou, Xu et al. 2003). In chondrocytes MEF2C protein has
been found to have a central role in endochondral ossification, more specifically, in
chondrocyte hypertrophy and terminal differentiation. In the murine growth plate HDAC4,
and in general class II HDACs, form an inhibiting complex with MEF2C halting its function
as a regulator of hypertrophy related genes such as RUNX2 and COL10A1 (Vega, Matsuda
et al. 2004, Arnold, Kim et al. 2007)
??????????????? ??????????????????????????????? ?????????????????????????????????
expression. In HACs there is clear evidence that MEF2C mRNA and protein up-regulation
follows the pattern of SOX9 (hypoxic inducible gene in HACs), and more in general, of
hypoxia-inducible genes. MEF2C null mice die at the E9.5 from cardiovascular defects
whereas MEF2A null mice die perinatally (Lin, Schwarz et al. 1997). In this context,
Krishnan et al show that HIF-1? transcription factor drives the expression of MEF2C and
consequently of the sarcomere protein titin. (Krishnan, Ahuja et al. 2008). However, we have
found that MEF2C expression is specifically HIF-2?? and not HIF-1?? dependent in adult
HACs. Whether this HIF-2? dependence of MEF2C is cartilage-specific, or occurs in other
tissues remains to be seen. However, it certainly makes sense from a cartilage perspective
since we have shown that HIF-2?? is a pro-anabolic regulator of human cartilage through its
direct activation of SOX9 transcription (Lafont, Talma et al. 2007, Thoms, Dudek et al.
2013).
For the first time, we identify MEF2C as new hypoxia-inducible gene in adult
?????????? ???????? ??? ??????? ???? ????? ???????????? ???????? ????? ??????????? ??? ?????? ???
through direct or indirect activation by HIF-2? and SOX9 remains to be seen.
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4.8.2 Hypoxia induces up-regulation of MEF2C gene expression without
affecting mRNA half-life
mRNA post-transcriptional regulation is a key step in the control of gene expression
in metazoans (Chen, Ezzeddine et al. 2008). Stability of individual mRNAs can change in
response to diverse physiological and extracellular stimuli in a wide range of biological
processes, e.g. inflammation and tumourgenesis (Dibbens, Miller et al. 1999). Hypoxia could
directly mediate changes in numerous mRNAs like VEGF, GLUT-1 and EPO (Semenza
1998). Moreover, hypoxia regulates the expression microRNAs that can alter the cellular
????????????????????????????????????? ???????????????????????????????????????????????????
of different genes creating a signalling network that coordinates different mRNAs. Our
laboratory has previously shown that microRNAs are critical for SOX9 and COL2A1
expression in HACs (Dudek, Lafont et al. 2010, Martinez-Sanchez and Murphy 2013).
From the work detailed in this chapter, we found that hypoxia increases MEF2C
mRNA levels, but does not alter the half-life of the MEF2C mRNA transcript, thus indicating
that the mRNA induction is due to transcriptional activation of the MEF2C gene rather than a
post-transcriptional mechanism.
4.8.3 MEF2C, like SOX9, is rapidly upregulated by hypoxia
SOX9 mRNA can be defined as early response in HACs since its mRNA is up-
regulated after only 5 hours of hypoxic treatment. In previous work in our laboratory, we
???????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????
detectable after 1h of hypoxia (or DMOG treatment). Mammalian cells continuously adapt to
external and internal changes. As a consequence biochemical networks are never static
(Hayles, Yellaboina et al. 2010). The biochemical networks are hierarchically organised in
mammalian cells, and signalling networks directly influence transcription factors
(transcription networks) which modulate the gene expression in order to provide the right
????????? ??? ?????????? ??????????????? ??? ?????? ???? ??????? ??????????? ???????? ?????????
influences the expression of the SOX9 mRNA which occurs earlier than the CAIX gene, a
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SOX9 protein up-regulation. Interestingly, SOX9 targets the essential matrix gene COL2A1
and the long non-coding mRNA H19, which both show, perhaps not unexpectedly, a slower
response to hypoxia. This wave of transcriptional events could underline the existence of and
pre-ordered genetic network which has as a prerogative the promotion of the HAC phenotype
itself. In this context MEF2C mRNA showed a variable response to hypoxia at early time
points (due to a natural variation of its expression among different donors) but, like SOX9,
MEF2C tends to be rapidly induced by hypoxia. Whether this could point a possible
involvement of TF MEF2C in the transcriptional control of the HAC phenotype will be the
topic of the following chapter.
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5.1 Introduction
The family of Myocyte Enhancer Factor 2 (MEF2) transcription factors is the
fulcrum of several transcriptional programmes that involve cellular differentiation and
organogenesis (Lin, Schwarz et al. 1997, Arnold, Kim et al. 2007, Miller, Swartz et al. 2007,
Potthoff and Olson 2007, Verzi, Agarwal et al. 2007, Gerstein 2009, Agarwal, Verzi et al.
2011, Kramer, Baertschi et al. 2012). Among the 4 genes of the MEF2 family MEF2C has
been found to be directly involved in bone development and chondrocyte hypertrophy
(Arnold, Kim et al. 2007). During endochondral ossification committed mesenchymal cells
differentiate into chondrocytes which then undergo hypertrophy (Kronenberg 2003). The
ultimate function of the hypertrophic chondrocyte is to provide a matrix scaffold for the
formation of new bone. Arnold and colleagues demonstrated that the deletion of the MEF2C
gene (using a Col2-CRE system) in mice caused the disruption of bone formation processes
particularly impairing the final chondrocyte differentiation towards hypertrophy (Arnold,
Kim et al. 2007). Recently, Dy et al showed that MEF2C regulates, along with SOX9
transcription factor, one of the main components of the hypertrophic ECM - the COL10A1
gene (Dy, Wang et al. 2012). MEF2C is also involved in regulation of the ECM during
development of the heart in mice through directly binding regulatory elements of the cartilage
link protein 1 (Crtl1) gene (Lockhart, Wirrig et al. 2013).
Most of what we know about MEF2C function is deduced from murine studies; while
MEF2C function is completely unknown in human articular cartilage. In a previous
microarray study in our laboratory many genes relevant for the human articular chondrocyte
(HAC) phenotype were identified as hypoxia inducible genes. From the previously described
work of this thesis we show that MEF2C is present in human articular cartilage with a largely
nuclear localisation and its expression is hypoxia inducible and HIF-2? and SOX9
dependent.
In this chapter we provide further important experimental evidence on the function of
MEF2C and identify it as a new and important transcriptional regulator of the cartilage
master regulator gene SOX9.
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5.2 SOX9 gene expression is MEF2C-dependent in HACs
In order to study the function of MEF2C in HACs, in initial experiments we silenced
expression of the MEF2C gene. Passaged HACs from 11 different donors (10-62 years old,
average age 25 years, 2 females and 9 males) were transfected with sequence-specific small
interfering RNA (siRNA) against MEF2C, and cultured in 20% O2 for 24 hours and
subsequently moved to hypoxia (1% O2) for 48 hours. RT-qPCR was used to assess the
silencing efficiency (75%), and the effects of the knockdown on other potentially relevant
mRNAs. Surprisingly, quantification of mRNAs revealed that the total SOX9 mRNA levels
decreased in MEF2C depleted HACs. This effect occurred in both 20% and 1% O2 tension
(FIG. 5.2, average decrease compared to the siRNA control: 40% in normoxia and 60% in
hypoxia). Western blotting from 7 different donors showed a similar effect on SOX9 protein
levels upon MEF2C depletion (FIG. 5.2.1). These experiments also confirmed the SOX9 and
MEF2C mRNA up-regulation by hypoxia noted in previous experiments. Validation
experiments with alternative siRNA oligonucleotides are presented in a dedicated section
later in this chapter (section 5.5).
Our group has previously shown that SOX9 expression is enhanced by hypoxia
???????????????????????????????????????????????????? ????????????????????????????????????
We therefore investigated the possibility that MEF2C could be regulating SOX9 expression
via HIF-2???????????????????????????????????????????????????????????????????????????
5.2.2) or protein levels (FIG. 5.2.3). SOX9 is the master regulator of the chondrocyte
phenotype, directly controlling the expression of the major matrix genes such as COL2A1
and COL9A1 (Lefebvre, Huang et al. 1997, Bi, Deng et al. 1999, Genzer and Bridgewater
2007). We therefore quantified the expression of COL2A1 and COL9A1 mRNA in order to
verify whether the decreasing of SOX9 due to the MEF2C silencing was functionally relevant
for the chondrocyte phenotype. As expected, expression of both SOX9 target genes was
decreased compared to controls (FIG. 5.2.4).
As previously mentioned, an identified gene target of SOX9 and MEF2C in the
developing murine growth plate is COL10A1 (Dy, Wang et al. 2012). Type 10 collagen is a
key component of the hypertrophic ECM and is also thought to be expressed by human
osteoarthritic cartilage (Dreier 2010). However, we report that in non-diseased HACs,
COL10A1 is lowly expressed and is not affected by MEF2C silencing (FIG. 5.2.5).
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Finally, we studied the effect on gene expression of potential MEF2C targets
previously identified in murine tissue which are involved in basic mechanisms of genetic
expression control or in ECM biology. HDAC4/9 gene codes for proteins often involved in
chromatin re-modelling has and have been demonstrated to be both regulators and targets of
MEF2C protein; while TIMP1 is a metallo-proteinase inhibitor and is involved in the ECM
biology and has been shown to be an indirect MEF2C target during vascularisation (Potthoff
and Olson 2007). However, in our experiments HDAC4/9 and TIMP1 expression were not
influenced by MEF2C silencing in HACs (FIG. 5.2.6).
FIGURE 5.2. Silencing of MEF2C reduces SOX9 mRNA levels. HACs (passage 1 or 2 monolayer
cultures) were transfected with MEF2C targeting oligos (siMEF2C) and cultured for 2 days in 20% or
1% O2. MEF2C (A) and SOX9 (B) mRNA levels were quantified using RT-qPCR and expressed
relative to 20% O2 levels. Gene expression was normalised to RPLP0. For greater clarity the graph in
panel (C) shows the SOX9 mRNA quantification in normoxia (from data in panel B). Data show the
expression average (± S.E.M.) measured in 11 independent experiments (i.e. cells from 11 different
donors; N 2, 7, 8(x2), 9, 10, 12, 14, 23, 24, 28). Note: **P < 0.01, ***P < 0.001, ****P < 0.0001 ;
siCTR – control siRNA. For explanation of the N number see Table 2.2.1.
***
********
***
*** **
***
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FIGURE 5.2.1. Silencing of MEF2C reduces SOX9 protein levels. HACs (passage 1 or 2
monolayer cultures) were transfected with MEF2C targeting oligos (si MEF2C) and cultured for 2
days in 20% or 1% oxygen tension. Western blots of HAC cultures from 7 different donors are shown.
Note: ?-TUB – ?-tubulin. For explanation of the N number see Table 2.2.1.
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FIGURE 5.2.2. Silencing of MEF2C does not affect EPAS1 (HIF-2?) gene expression levels.
HACs (passage 1 or 2 monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C)
and cultured for 2 days in 20% or 1% oxygen tension EPAS1 mRNA levels were quantified using RT-
qPCR and expressed relative to 20% oxygen levels. Gene expression was normalised to RPLP0. Data
show the expression average (±S.E.M.) measured in 8 independent experiments (i.e. cells from 8
different donors; N 6, 7, 8 (x2), 9 10, 12, 23 ). For explanation of the N number see Table 2.2.1.
??????????????????????????? ??????????????????????????????????????????? HACs (passage 1 or 2
monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C) and cultured for 2
days 1% oxygen tension. Western blots of HAC cultures from 3 different donors are shown. Note: ?-
TUB – ?-tubulin. For explanation of the N number see Table 2.2.1.
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FIGURE 5.2.4. Silencing of MEF2C reduces expression of the classical SOX9 gene targets.
HACs (passage 1 or 2 monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C)
and cultured for 2 days in 20% or 1% oxygen tension.COL2A1 and COL9A1 mRNA levels were
quantified using RT-qPCR and expressed relative to 20% oxygen levels. Gene expression was
normalised to RPLP0. Data show the expression average (±S.E.M.) measured in 11 independent
experiments (i.e. cells from 11 different donors for COL2A1, 2 different donors for COL9A1; N 2, 7,
8(x2), 9, 10, 12, 14, 23, 24, 28 ). Note: **P < 0.01, ****P < 0.0001; siCTR – control siRNA. For
explanation of the N number see Table 2.2.1.
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FIGURE 5.2.5. Silencing of MEF2C does not affect COL10A1 gene expression. HACs (passage 1
or 2 monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C) and cultured for 2
days in 20% or 1% oxygen tension. COL10A1 levels were quantified using RT-qPCR and expressed
relative to 20% oxygen levels. Gene expression was normalised to RPLP0. Data show the expression
average (±S.E.M.) measured in 6 independent experiments (i.e. cells from 6 different donors, N 2 (x2)
, 10, 12, 14, 19). Note: siCTR – control siRNA. For explanation of the N number see Table 2.2.1.
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FIGURE 5.2.6. Silencing of MEF2C does not affect HDAC4, HDAC9 and TIMP1 gene
expression. HACs (passage 1 or 2 monolayer cultures) were transfected MEF2C targeting oligos
(siMEF2C) and cultured for 2 days in 20% or 1% oxygen tension. HDAC4, HDAC9 and
TIMP1mRNA levels were quantified using RT-qPCR and expressed relative to 20% oxygen levels.
Gene expression was normalised to RPLP0. Data show the expression average (±S.E.M.) measured in
3 (HDAC9;N 9, 10, 12), 4 (TIMP1; N9, 10, 12, 23), and 5 (HDAC4; N9, 10, 12, 23, 24) independent
experiments. Note: siCTR – control siRNA. For explanation of the N number see Table 2.2.1.
5.3 MEF2C gene silencing greatly impairs hypoxic induction of SOX9
We next investigated the effect of MEF2C depletion during the early stage of the
SOX9 hypoxic up-regulation. Passaged HACs from 4 different donors (from a range of 13-23
years old, mean age 17.3 years, 1 female, 3 males) were transfected with specific siRNA
against MEF2C, and as before cultured in 20% O2, and subsequently moved to hypoxia (1%
O2) (InVIVO2 400). Considering that we previously observed that the minimal time required
for SOX9 hypoxic up-regulation was 5 hours, MEF2C–depleted HACs were harvested after
5, 10, 24 hours of hypoxia. We used RT-qPCR to assess of the silencing efficiency (85%),
and the effects of MEF2C depletion on SOX9 mRNAs (FIG. 5.3). The mRNA quantification
and western blotting analysis revealed that up-regulation of SOX9 gene expression is
impaired during the early stage of hypoxia adaptation when the MEF2C protein is depleted in
human articular chondrocytes (FIG. 5.3, 5.3.1).
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The role of MEF2C was further confirmed in short-term DMOG treatment
experiments. Passaged HACs from 3 different donors were transfected with specific siRNA
against MEF2C, cultured in 20% O2 and subsequently treated for 5 hours with 500 uM of the
hypoxia mimetic DMOG. Experiments confirmed the involvement of MEF2C protein in
hypoxic induction of SOX9. As expected from previous hypoxia experiments (FIG. 5.2.3),
????????????????????????????????????????????????????????????????????????????????????????
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FIGURE 5.3. Silencing of MEF2C abolishes hypoxic induction of SOX9 mRNA. HACs (passage
1 or 2 monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C) and cultured for
2 days in 20% O2 and then lysed after 5, 10, or 24 hours of hypoxia (with relevant controls). MEF2C
and SOX9 mRNA levels were quantified using RT-qPCR and gene expression was normalised to
RPLP0. In panel (A) data were expressed relative to 5h normoxia levels while in panel (B) data were
expressed relative to siCTR 1% O2 levels for each time point. Data show the expression average
(±S.E.M.) measured in 4 independent experiments(N 2, 12, 16, 32). Note: *P < 0.05, **P < 0.01;***P
< 0.001; siCTR – control siRNA; h – hours. For explanation of the N number see Table 2.2.1.
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FIGURE 5.3.1. Silencing of MEF2C abolishes hypoxic induction of SOX9 protein. HACs
(passage 1 or 2 monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C) and
cultured for 2 days in 20% and then lysed after 5, 10, or 24 hours of hypoxia (with relevant controls).
Western blots of HAC cultures from two different donors are shown. Note: siCTR- control siRNA,;
?-TUB – ?-tubulin. For explanation of the N number see Table 2.2.1.
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treatment. HACs (passage 1 or 2 monolayer cultures) were transfected with MEFC targeting oligos
(siMEF2C) and cultured for 5 hours in DMOG (500uM). Western blots of HAC cultures from three
different donors are shown. Note: ?-TUB – ?-tubulin; siCTR – control siRNA; DMOG -
dimethyloxalylglycine. siCTR and siMEF2C, in the absence of DMOG, had vehicle added. For
explanation of the N number see Table 2.2.1.
.
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5.4 MEF2C is required for maintenance of elevated SOX9 levels in
continued hypoxia
In order to investigate whether MEF2C protein was required for SOX9 expression
even after adaptation to hypoxia, we depleted MEF2C in passaged HACs that had previously
been cultured for 24 hours in hypoxia (InVIVO2 400). Following hypoxia incubation, cells
were transfected with specific MEF2C siRNA using 1% O2 pre-equilibrated reagents and
cultured for a further 48 hours in hypoxia (1% O2). RT-qPCR analysis and western blotting
confirmed the dependence of SOX9 expression on MEF2C (FIG. 5.4, FIG. 5.4.1).
These experiments revealed that MEF2C function, specifically its action on SOX9, is
not merely a transient response to hypoxia but is required for maintenance of elevated SOX9
expression levels in continued hypoxia.
* *
* *
FIGURE 5.4. Silencing of MEF2C reduces SOX9 mRNA levels in hypoxia pre-adapted HACs.
HACs (passage 1 or 2 monolayer cultures), after being cultured for 1% oxygen were transfected with
MEF2C targeting oligos and cultured for 2 days in hypoxia. A parallel culture was transfected with
control siRNA and cultured 3 days in normoxia. MEF2C and SOX9 mRNA levels were quantified
using RT-qPCR and expressed relative to 20% oxygen levels. Gene expression was normalised to
RPLP0. Data show the expression average (±S.E.M.) measured in 3 independent experiments. (N 12,
27 (x2), ) Note: Note: *P < 0.05, siCTR –control siRNA. For explanation of the N number see Table
2.2.1.
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FIGURE 5.4.1. Silencing of MEF2C reduces SOX9 protein expression in hypoxia pre-adapted
HACs. HACs (passage 1 or 2 monolayer cultures), after being cultured for 1% oxygen were
transfected with MEF2C targeting oligos and cultured for 2 days in hypoxia. A parallel culture was
transfected with control siRNA and cultured 3 days in normoxia.Western blots of HAC cultures from
two different donors are shown. Note: siCTR- control siRNA; ?-TUB – ?-tubulin. For explanation of
the N number see Table 2.2.1.
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5.5 Study of MEF2C function with different specific small-interfering
RNAs
Gene silencing is now one of the most common techniques in gene expression studies.
RNA interference (RNAi) is a powerful technique that offers great target sensitivity (Jackson
and Linsley 2010). However, recent literature shows how siRNAs can affect ‘non-target’
????????????????????????????????????? ?????????????????????????????????????????????????????
like off-target effects. Another way for the siRNA to generate off-target effects is by blocking
the microRNA machinery. This issue is particularly affected by high amount of siRNA being
transfected (>30nM) or by the delivery protocol (Jackson and Linsley 2010).
In order to confirm the specificity of our siRNAs, we transfected in all silencing
experiments (in a parallel HAC culture) a scrambled sequence (AMBION) with no similarity
with any known transcripts. In addition, all siRNAs have been used at a concentration of
10nM.
Different specific siRNAs for an individual transcript with comparable efficiency
should cause the same effect on the phenotype or genetic pathway of interest. Any possible
discrepancy could be indicative of an off-target effect. We compared the effects of MEF2C
silencing by transfecting two different oligos (named #2 and #3, pre-validated and pre-
designed oligos from AMBION) in independent experiments.
Silencing of MEF2C using with oligo #2 (s8654 AMBION) and #3 (143535
AMBION) showed the same effect on SOX9 gene expression already observed in previous
experiments where oligo #1 was used (s8653 AMBION) (FIG. 5.5, 5.5.1).
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FIGURE 5.5. Effects of different MEF2C targeting siRNA. (A) HACs (passage 1 or 2 monolayer
cultures) were transfected with 2 different MEF2C targeting oligos (#1 and #2) and cultured for 2
days in 20% oxygen tension. MEF2C and SOX9 mRNA levels were quantified using RT-qPCR and
expressed relative to siCTR. Gene expression was normalised to RPLP0. Data show the expression
average (±S.E.M.) measured in 3 independent experiments (i.e. cells from 3 different donors; N 2,
28). (B) HACs (passage 1 or 2 monolayer cultures) were transfected with 2 different MEF2C
targeting oligo s(#1 and #2) and cultured for 2 days in 20% oxygen tension and for 2 days in 1%
oxygen tension Western blots reduced SOX9 levels with both MEF2C siRNAs in both normoxia and
hypoxia in cultures from two different donors. Note: **P < 0.01, ***P < 0.001, siCTR – control
siRNA;??-TUB – ?-tubulin. For explanation of the N number see Table 2.2.1.
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FIGURE 5.5.1. Effects of different MEF2C targeting siRNA. (A) HACs (passage 1 or 2 monolayer
cultures) were transfected with a third MEF2C targeting oligo (#3) and cultured for 2 days in 20%
oxygen tension. MEF2C and SOX9 mRNA levels were quantified using RT-qPCR and expressed
relative to 20% oxygen tension. Gene expression was normalised to RPLP0. Data show the expression
average (±S.E.M.) measured in 3 independent experiments (i.e. cells from 3 different donors; N 2; 12;
21).(B) Western blots showed reduced SOX9 protein levels in MEF2C depleted cultures as noted for
previous MEF2C siRNAs. Note: *P < 0.05, siCTR – control siRNA;??-TUB – ?-tubulin. For
explanation of the N number see Table 2.2.1.
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5.6 SOX9 mRNA stability
An important step of gene expression in mammalian cells is the control of mRNA
stability. Cytoplasmic mRNA half-life could be regulated by different mechanisms such as
deadenylation, decay directed by AU-rich elements (AREs), decay mediated by destabilising
elements in protein-coding regions, nonsense-mediated mRNA decay (NMD) or decay
directed by microRNAs (miRNAs) (Chen, Ezzeddine et al. 2008). In order to understand the
mechanism behind the regulation of SOX9 gene expression mediated by MEF2C, we next
investigated whether MEF2C can affect SOX9 mRNA stability.
5.6.1 SOX9 mRNA expression levels in control conditions
HACs from 2 donors (experiment done in duplicate) were transfected with specific
siCTR (+vehicle) and specific siRNA against MEF2C. Cells were cultured for 48 hours in
20% O2 and 1% O2, and then treated with the transcription inhibitor, Actinomycin-D (5uM,
Sigma). Cells were harvested 1h, 2h, 3h, and 4h following Actinomycin-D treatment. With
the aim of establishing the SOX9 mRNA half-life, the contribution of different control
conditions (i.e. normoxia, hypoxia, siRNA control and vehicle) to the mRNA steady state
expression levels was first assessed.
RT-qPCR analysis revealed that the total quantity of SOX9 at the beginning and at the
end of our 4 hour assay is not significantly changing in normoxia or hypoxia (+ vehicle and
siCTR) (FIG. 5.6.1.1 A). Furthermore, when the cells are not subjected to Actinomycin D
treatment, the total SOX9 mRNA quantity is stable in MEF2C-depelted HACs over the 4
hour experimental time course (FIG. 5.6.1.1 B-C). The quantification of total individual
mRNAs confirmed the findings of our previous experiments: SOX9 hypoxic up-regulation
and the SOX9 decrease in MEF2C depleted HACs (FIG. 5.6.1.1). The efficiency of the
MEF2C silencing was assessed by RT-qPCR (FIG. 5.6.1).
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5.6.2 Decreased SOX9 mRNA half-life in hypoxia
Once we established that SOX9 expression levels do not fluctuate during the
experimental time course (4 hours) under control conditions we consequently quantified the
half-life of SOX9 mRNA in cells treated with 5uM Actinomycin-D and siCTR (FIG. 5.6.2).
By using a linear regression analysis of the Graph-Pad 6.0 software, we identified the line
that best fits the data, and we obtained the decay rate constant from the slope of a semi-
logarithmic plot of SOX9 mRNA levels as a function of time (FIG. 5.6.2 A). Subsequently,
the decay rate has been used to determine the mRNA half-life using Graph-Pad 6.0 software.
Statistical analysis revealed that SOX9 mRNA shows a shorter half-life in hypoxic conditions
(2.1 hours in normoxia versus 1 hour in hypoxia) (FIG. 5.6.2 B).
5.6.3 Effects of MEF2C silencing on SOX9 mRNA half-life
We next investigated if MEF2C affects SOX9 mRNA stability. Surprisingly, MEF2C
silencing decreases SOX9 mRNA stability in an oxygen-dependent fashion, i.e. in normoxic
conditions only.
In fact, SOX9 transcripts in MEF2C depleted HACs cultured in normoxia showed a reduction
of their half-life of 50% (FIG. 5.6.3). However there was no difference in SOX9 half-life
measured in MEF2C depleted HACs cultured in hypoxia compared to the control hypoxic
conditions (siCTR in hypoxia) (FIG. 5.6.3.1).
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FIGURE 5.6.1.MEF2C depleted levels are stable during 4 hours incubation in normoxia and
hypoxia (with vehicle). HACs (passage 1 monolayer cultures) were transfected with MEF2C
targeting oligos (siMEF2C) and cultured for 48 hours in 20% or 1% oxygen tension. Cells were
harvested after 1, 2, 3 and 4 hours following a media change containing vehicle (DMSO). MEF2C
mRNA levels were quantified using RT-qPCR and expressed relative to 0 hours siCTR levels. Gene
expression was normalised to RPLP0. Data show the expression average (±S.E.M.). MEF2C mRNA
levels are efficiently silenced in normoxia (A) and in hypoxia (B) and are stable during 4 hours’
treatment with vehicle. Values are the mean of 4 different experiments using cells from 2 different
donors (N 16, 32). Note: siCTR-control siRNA siMEF2C – MEF2C targeting siRNA. For explanation
of the N number see Table 2.2.1
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FIGURE 5.6.1.1. MEF2C silencing stably reduces SOX9 steady state mRNA levels in control
conditions. HACs (passage 1 monolayer cultures) were transfected with MEF2C targeting oligos
(siMEF2C) and cultured for 48 hours in 20% or 1% oxygen tension. Cells were harvested after 1, 2, 3
and 4 hours following a media change containing vehicle (DMSO). SOX9 mRNA levels were
quantified using RT-qPCR and expressed relative to 0 hours siCTR levels. Gene expression was
normalised to RPLP0. Data show the expression average (±S.E.M.). SOX9 mRNA levels are
upregulated by hypoxia (A) and decreased by MEF2C silencing in both normoxia (B) and hypoxia
(C), as expected. Values are the mean of 4 different experiments using cells from 2 different donors
(N 16, 32). Note: siCTR-control siRNA siMEF2C – MEF2C targeting siRNA. For explanation of the
N number see Table 2.2.1.
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FIGURE 5.6.2. Effect of hypoxia on SOX9 mRNA stability. Confluent HACs (passage 1) were
cultured for 48 hours in normoxia (20% O2) or hypoxia (1% O2) before treament with 5uM
Actinomycin D (ACTD). Samples were harvested after 1, 2, 3 and 4 hours of Actinomycin D
treatment. SOX9 levels were quantified using RT-qPCR and expressed relative to 0 hours. Gene
expression was normalised to RPLP0. Data show the expression average (±S.E.M.). SOX9 mRNA
decay curves (A) and calculated half-lives (B). Values are the mean of 4 different experiments and
HACs from 2 different donors (N 16, 32). Note: siCTR – control siRNA; **P < 0.01. For explanation
of the N number see Table 2.2.1.
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FIGURE 5.6.3. SOX9 mRNA stability is affected by MEF2C depletion in normoxia. HACs
(passage 1, monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C) and
cultured for 48 hours in normoxia. Subsequently, HACs cultures were treated with 5uM Actinomycin
D (ACTD) and harvested after 1, 2, 3 and 4 after treatment. Effects on SOX9 mRNA levels were
quantified using RT-qPCR and expressed relative to hours 0. Gene expression was normalised to
RPLP0. Data show the expression average (±S.E.M.). SOX9 mRNA decay curves (A) and calculated
half-lives (B). Values are the mean from 4 independent experiments (i.e. cells from 4 different donors;
N 16, 32). Note: siCTR- control siRNA; *P < 0.05. For explanation of the N number see Table 2.2.1.
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FIGURE 5.6.3.1. SOX9 mRNA stability is not affected by MEF2C depletion in hypoxia. HACs
(passage 1, monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C) 48 hours
in hypoxia. Subsequently, HACs cultures were treated with 5uM Actinomycin D (ACTD) and
harvested after 1, 2, 3 and 4 after treatment. Effects on SOX9 mRNA levels were quantified using
RT-qPCR and expressed relative to hours 0. Gene expression was normalised to RPLP0. Data show
the expression average (±S.E.M.). SOX9 mRNA decay curves (A) and calculated half-lives (B).
Values are the mean from 4 independent experiments (i.e. cells from 4 different donors; N 16, 32).
Note: siCTR- control siRNA. For explanation of the N number see Table 2.2.1.
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5.7 Discussion
In this chapter we uncover an important role of MEF2C in human chondrocytes.
MEF2C is expressed in HACs and its expression is enhanced when HACs are cultured in low
oxygen conditions which more closely approximate those occurring in vivo in human
articular cartilage (Lundoles.K 1970, Brighton and Heppenstall 1971, Silver 1975, Murphy
?????????? ??????????? ??????? ????? ????? ?????????????? ??? ?????????? ??? ??????? ??? ????????
conditions (Lafont, Talma et al. 2007). However, our silencing experiments reveal that SOX9
gene expression is highly MEF2C dependent (in both normoxia and hypoxia). The most
immediate way in which transcription factors (TFs) can modulate specific gene expression is
through binding directly to regulatory elements of target genes. Nevertheless, TFs can
regulate secondary TFs, or alternatively proteins or miRNAs involved in post-transcriptional
and translational regulation. For example, MEF2 family members have been shown to be
capable of indirect regulation of gene expression by driving the transcription of miRNAs
(Potthoff and Olson 2007). Work presented in this chapter shows that 1) MEF2C is a newly
identified regulator of SOX9 gene expression; and 2) MEF2C does not regulate hypoxic
induction of SOX9 by affecting SOX9 mRNA stability suggesting a (direct or indirect)
transcriptional activation mechanism.
5.7.1 MEF2C as a new regulator of SOX9 gene expression
MEF2C protein is a multi-function transcription factor involved in different
developmental programmes, from myocyte differentiation to chondrocyte hypertrophy
(Arnold, Kim et al. 2007). MEF2C belongs to a wider transcription factor family that shows
high evolutionary conservation (Potthoff and Olson 2007). All members of this family
contain a MADS domain with an adjacent motif termed the MEF2 domain. These domains
mediate dimerisation, DNA binding, and co-factor interactions (Martin, Miano et al. 1994,
Black and Olson 1998, McKinsey, Zhang et al. 2000, Potthoff and Olson 2007).The
transcriptional activation domain is divergent among MEF2 family members. MEF2C relies
on activation signals from extracellular stimuli, and the co-operation of co-activators,
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moreover, it appears to need interaction with other transcription factors to activate and drive
the expression of gene targets (Black and Olson 1998, Potthoff and Olson 2007).
MEF2C transcription factor is expressed both in embryonic and adult tissue. In adult
mammals MEF2C protein has been found to be expressed in lymphocytes, neural synapses
and muscle, whereas there is no data available for the adult cartilage (Barbosa, Kim et al.
2008, Agarwal, Verzi et al. 2011). In the bone development process MEF2C drives the
expression of genes relevant for hypertrophic differentiation of chondrocytes (Arnold, Kim et
al. 2007, Potthoff and Olson 2007). Several transcription factors are involved in control of
chondrocyte hypertrophy and osteoblast differentiation. Among them there is the member of
the Runt-family, RUNX2. Mice deficient in Runx2 show an early arrest of chondrocyte
hypertrophy with subsequently impaired bone formation (Komori, Yagi et al. 1997, Otto,
Thornell et al. 1997, Zheng, Zhou et al. 2003). In their work, Arnold and colleagues showed
that MEF2C was directly able to affect chondrocyte hypertrophy, not only by directly
regulating the expression of matrix genes like Col10a1, but also by indirectly regulating
Runx2 expression (Arnold, Kim et al. 2007). Moreover, Vega et al. reported HDAC4, a class
II HDAC, is a repressor of chondrocyte hypertrophy forming an inhibitor complex together
with MEF2C (Vega, Matsuda et al. 2004). After the conformational change caused by
MEF2C phosphorylation, the HADC protein is released leaving MEF2C free to interact with
co-activators p300/CBP thus enhancing gene target expression. (Sartorelli, Huang et al. 1997)
(Al Madhoun, Mehta et al. 2011). MEF2C often needs a transcriptional partner to activate the
expression of target genes (Sartorelli, Huang et al. 1997). In hypertrophic chondrocytes,
Mef2c drives the expression of matrix gene Col10 together with Sox9, which binds a
sequence 20 bp downstream of the Mef2c binding site on the Col10a1 proximal promoter
(Dy, Wang et al. 2012).
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regulator of the chondrocyte phenotype (Lafont, Talma et al. 2008). The stabilisation of HIF
protein is at the core of the HIF-mediated hypoxic response. Stabilised HIF proteins form a
heterodimer complex consisting of a ?? ???????? ???? ?? ??????????????? ?????????? ??????????
???????? ??? ?????????????????????????????? ??????????????????????????????????????????????
(PHD1, PHD2 and PHD3) which enable the interaction with the von Hippel Lindau (VHL)
protein and, subsequently, the ubiquitination and proteasomal degradation of the HIF-?
subunit (Schofield and Ratcliffe 2004). In HACs, predominantly the inhibition of the prolyl
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Hypoxia Response Elements (HREs) on target genes, activating and enhancing their
transcription. We previously identified SOX9 as a hypoxia responsive gene in HACs (Thoms,
Dudek et al. 2013), which activates a network of matrix genes including COL2A1, COL9,
AGN. Thus, following induction of SOX9 by hypoxia, a cascade of pro-chondrocytic genetic
events begins.
By depleting HACs of MEF2C we observed that the hypoxia-dependent enhancement
of SOX9 expression is virtually abolished. Furthermore, our experiments showed that
MEF2C is necessary not just for initial hypoxic induction of SOX9 gene expression, but also
for maintaining elevated SOX9 expression levels in prolonged hypoxic conditions, which, of
course are the conditions found in vivo in this avascular tissue. As already reported in Chapter
?????????????????????????????????????????????????????????????????????????????????????
thus conclude that we have discovered a vitally important new function of MEF2C - namely
as a key regulator of SOX9 expression, which appears to be part of a wider transcriptional
network regulating expression of the HAC phenotype.
5.7.2 MEF2C does not affect SOX9 mRNA stability in hypoxia
Gene expression occurs by a multifaceted process by which cells integrate, coordinate
and drive the flow of information to/from the genome. A significant part of this complex
regulation is the post-transcriptional control of the gene expression that regulates the steady-
state of mRNAs along with the transcriptional rate. While transcription rates are regulated by
various classes of DNA/chromatin binding proteins, the post-transcriptional mRNA levels are
controlled by the RNA binding proteins or miRNA effector complexes which affect transcript
stability (Chen, Ezzeddine et al. 2008, Fuda, Ardehali et al. 2009).
The MEF2 family plays a central role in muscle development (Andres, Cervera et al.
1995). Differentiating smooth muscle cells adopt a lineage-specific gene expression pattern
partly through transcription factors such as myogenin, HDAC class II and MEF2 itself.
MEF2 protein can, alternatively, drive the expression of muscle effectors by the regulation of
transcripts encoding for the precursor of various miRNAs (miR-1,-113 and -206) which then
disrupt translation or mRNA stability of their targets (Potthoff and Olson 2007). In our
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experiments we aimed to uncover whether MEF2C regulated SOX9 via controlling its mRNA
stability. Our data shows that the SOX9 mRNA stability is not affected by MEF2C silencing
in HACs cultured in low oxygen conditions thus indicating that hypoxic induction of SOX9 is
most likely mediated by MEF2C through (direct or indirect) transcriptional activation.
We here demonstrate that hypoxia, although increasing SOX9 mRNA levels, actually
decreases the half-life of SOX9 mRNA. Interestingly, Lafont and colleagues showed no
difference in SOX9 half-life measured in hypoxia and normoxia, which could be principally
due to a different experimental design: different time course (1.5, 3, 6 hours) use of higher
Actinomycin-D dose (potentially toxic for cells) and use of a conventional hypoxic incubator
instead of a hypoxic workstation (which was used in the current experiments). However, our
results are in line with Tew and co-workers who reported that SOX9 mRNA half-life is
decreased in the presence of higher steady state levels of the transcript (Tew and Clegg
2011). Hypoxia is a pro-chondrocytic stimulus in HACs supporting expression of the
differentiated HAC phenotype in vitro (Lafont, Talma et al. 2007, Thoms, Dudek et al. 2013).
Tew and co-workers have demonstrated that SOX9 mRNA half-life is increased with the de-
differentiation of HACs perhaps due to mechanisms attempting to counteract the de-
differentiation process itself. Thus, the increased SOX9 half-life in passaged HACs in
normoxia (compared to more physiological hypoxia) could represent more of a peculiar
adaptation to culturing conditions rather than a physiological feature of HACs.
In the physiological conditions of hypoxia MEF2C depletion has no effect on SOX9
mRNA stability (despite increasing its steady state levels) strongly suggesting that MEF2C is
(directly or indirectly) involved in the transcriptional induction (synthesis) of SOX9 mRNA.
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6.1 Introduction
The transcription factor Distal-Less-homeboX-5 (DLX5), along with Distal-Less-
homeboX-6 (DLX6), is required for the craniofacial, axial and appendicular skeletal
development (Robledo, Rajan et al. 2002, Verzi, Agarwal et al. 2007). Recently,
heterozygous mutations in the DLX5 gene that result in a less active form of DLX5 protein
have been directly linked with Split Hand/Foot malformation (SHSM). This congenital
disease, known as ectrodactyly, presents a phenotype that varies from mild syndactyly of
?????? ??? ????? ??????? ??? ??????? ???????????????????? ?????? ??? ?????? ??????? ???? ??? ???? ???????
Depletion of these genes can recapitulate SHSM abnormalities observed in murine models.
Moreover, MEF2C has been shown to regulate expression of DLX5/6 genes in conditional
knock-out mice (Robledo, Rajan et al. 2002) (Wang, Xin et al. 2014). A previous microarray
study published by our laboratory has shown that many genes potentially relevant for the
chondrocyte phenotype were hypoxia inducible like SOX9, MEF2C and the matrix gene
COL2A1 and AGN. Interestingly, DLX5 was among them.
In this chapter we present data indicating that DLX5 is a new hypoxia inducible gene
??????????????????????????????????????? ??????????????
6.2 Hypoxia up-regulates DLX5 gene expression in HACs
Passaged HACs from 6 different donors (10-35 years old, average age 22 years, 1
female, 5 males) were cultured in 20% O2 and 1% O2 for 48 hours. We used RT-qPCR to
assess the effects of hypoxia on DLX5 mRNA levels (FIG. 6.2). The mRNA quantification
revealed that DLX5 gene expression is increased by hypoxia, confirming our previous
findings.
We next studied the up-regulation kinetics of DLX5 gene expression during hypoxic
adaptation. HACs from 6 different donors (16-58 years old, average 32.8 years, 3 females 3
males) were seeded at 150,000 cells per 3.5 cm dish the day before the experiment and
cultured in the InVIVO2 400 workstation (1% O2, 37oC) with pre-equilibrated media. After 1,
5, 10 and 24 hours of hypoxia, HACs were harvested and RT-qPCR used to assess gene
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expression. The quantification of the mRNA expression reveals that DLX5, as already
showed for SOX9, is an early responsive gene (FIG. 6.2.1).
**
FIGURE 6.2. DLX5 mRNA expression is upregulated by hypoxia in HACs. HACs (passage 1 or 2
monolayer cultures) were incubated for 2 days in 20% or 1% oxygen tension. DLX5 mRNA levels
were quantified using RT-qPCR and expressed relative to 20% oxygen levels. Gene expression was
normalised to RPLP0. Data show the average (±S.E.M.) gene expression levels measured in 6
independent experiments (i.e. cells from 6 unique donors; N 2, 7, 8, 9, 10, 12). Note: **P < 0.01. For
explanation of the N number see Table 2.2.1.
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FIGURE 6.2.1. Hypoxia response of DLX5 mRNA in HACs. HACs (passage 1 or 2 monolayer
cultures) were incubated for 1, 5, 10, 24 hours in 20% or 1% oxygen tension. DLX5 mRNA level was
quantified using RT-qPCR and expressed relative to 1h, 20% oxygen levels. Gene expression was
normalised to RPLP0. Data show the expression average (±S.E.M.) measured in 5 independent
experiments (i.e. cells from 5 different donors; N 1, 9, 16, 29, 32). Note: *P < 0.05, **P < 0.01. For
explanation of the N number see Table 2.2.1.
6.3 The DLX5 transcription factor: HIF-2? and MEF2C dependence
In order to investigate the possible regulation of DLX5 by MEF2C in HACs, we
silenced the expression of MEF2C using RNAi. Passaged HACs from 6 different donors (10-
35 years old, average age 22 years, 1 female, 5 males) were transfected with specific siRNA
against MEF2C, cultured in 20% O2 and subsequently moved to hypoxia for 48 hours. We
used RT-qPCR to assess of the silencing efficiency of MEF2C (~75%). MEF2C depletion
significantly reduced DLX5 mRNA levels (FIG. 6.3.0, 15% in normoxia and 50% in
hypoxia).
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In order to further investigate the possible mechanisms behind regulation of DLX5
gene expression in HACs we silenced the expression of the EPAS1 gene which encodes HIF-
2?. Passaged HACs from 6 different donors (10-35 years old, average age 22 years, 1 female
5 males) were transfected with specific siRNA against EPAS1, cultured in 20% O2 and
subsequently moved to hypoxia for 48 hours. Surprisingly, depletion of HIF-2? significantly
reduced DLX5 mRNA levels even in normoxia, although the effect was more pronounced in
hypoxia (FIG. 6.3.1). In these experiments we identified DLX5 as a new hypoxia-inducible
(and HIF-2? dependent) gene. Furthermore we confirmed that DLX5 expression is regulated
by MEF2C in HACs. This suggested a potentially important role for DLX5 in HACs and this
was next investigated.
**
**** ** **
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FIGURE 6.3. Silencing of MEF2C reduces DLX5 mRNA levels. HACs (passage 1 or 2 monolayer
cultures) were transfected with MEF2C targeting oligos (siMEF2C) and cultured for 2 days in 20% or
1% oxygen tension. MEF2C and DLX5 mRNA levels were quantified using RT-qPCR and expressed
relative to 20% oxygen levels. Gene expression was normalised to RPLP0. Data show the expression
average (±S.E.M.) measured in 6 independent experiments (i.e. cells from 6 different donors; N 3, 7,
9, 10, 12, 32). Note: **P < 0.01; siCTR – control siRNA. For explanation of the N number see Table
2.2.1.
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FIGURE 6.3.1. Silencing of EPAS1 (HIF-2?) reduces DLX5 mRNA levels. HACs (passage 1 or 2
monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C) and cultured for 2
days in 20% or 1% oxygen tension. EPAS1 and DLX5 mRNA levels were quantified using RT-qPCR
and expressed relative to 20% oxygen levels. Gene expression was normalised to RPLP0. Data show
the expression average (±S.E.M.) measured in 6 independent experiments (i.e. cells from 6 different
donors; N 3, 7, 9, 10, 12, 32). Note: *P < 0.05, **P < 0.01, ***P < 0.001; siCTR – control siRNA. For
explanation of the N number see Table 2.2.1.
6.4 Effects of DLX5 silencing on SOX9 gene expression
MEF2C positively regulates the expression of SOX9 mRNA and we have shown in
previous chapters that this is likely to occur through transcriptional activation (either direct or
indirect). Considering that transcription factor DLX5 has been already shown to be a MEF2C
transcriptional target in murine cells and is affected by MEF2C silencing in HACs in our
experiments, we tested the hypothesis that DLX5 (lying downstream of MEF2C) could play a
role in the control of SOX9 gene expression.
Passaged HACs from 6 different donors (10-35 years old, average age 22 years, 1
female 5 males) were transfected with two specific siRNA against DLX5, cultured in 20% O2
and subsequently moved to hypoxia for 48 hours. An effective depletion of DLX5 was
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confirmed at both the mRNA and protein level (FIG. 6.4.0, A-B). However, no effects on
SOX9 and COL2A1 mRNA expression were detected in DLX5 depleted HAC cultures (FIG.
6.4.0, C).
***
*******
*******
*
*
*
**
*
*
*
FIGURE 6.4. Silencing of DLX5 does not affect SOX9, or COL2A1 mRNA expression levels.
HACs (passage 1 or 2 monolayer cultures) were transfected with MEF2C targeting oligos (siMEF2C)
and cultured for 2 days in 20% or 1% oxygen tension. (A) RT-qPCR.and (B) western blotting were
used to assess the silencing efficiency of the DLXmRNA and protein. (C) MEF2C, SOX9 and
COL2A1 mRNA levels were quantified and expressed relative to 20% oxygen levels. Gene
expression was normalised to RPLP0. Data show the expression average (±S.E.M.) measured in 6
independent experiments (i.e. cells from 6 different donors: N 2, 3, 12(x2) 35, 36, 37). Note: *P <
0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; siCTR – control siRNA. For explanation of the N
number see Table 2.2.1..
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6.5 Discussion
DLX5 has been proposed to be a positive regulator of chondrocyte hypertrophy and
osteoblast differentiation (Zhu and Bendall 2009). First identified in mouse, DLX5 has been
found to map at 7q22 in an inverted-convergent configuration together with family member
DLX6 (Simeone, Acampora et al. 1994). Similarly, the human genes DLX-1/2 and DLX-5/6
show the same convergence and present the same mapping localisation to their murine
orthologues (USCS genome browser) (Wang, Xin et al. 2014).
DLX5 is expressed during murine development at the level of the ventral
diencephalon and basal telencephalon and after initial cartilage formation in mid-gestation
embryos (Simeone, Acampora et al. 1994). DLX5 null mice show a lethal phenotype that is
linked directly with the loss of bone mass (Samee, Geoffroy et al. 2008) as a consequence of
its involvement in RUNX2 expression in hypertrophic chondrocytes (Robledo, Rajan et al.
2002, Zhu and Bendall 2009) and RUNX2, OXSTERIX and OSTEOCALCIN in osteoblasts
(Samee, Geoffroy et al. 2008). Lack of the DLX5 protein has been directly linked with Split
Hand/Foot malformation (SHSM) (Wang, Xin et al. 2014), and depletion of this gene
recapitulates SHSM abnormalities in murine models (Robledo, Rajan et al. 2002).
SOX9 and MEF2C are essential transcription factors that orchestrate endochondral
ossification (Dy, Wang et al. 2012), and display overlapping expression with DLX5 (Verzi,
Agarwal et al. 2007, Zhu and Bendall 2009). Furthermore, recently it has been demonstrated
that Mef2c is an important regulator of Dlx-5/6 expression during cranio-facial development
(Verzi, Agarwal et al. 2007) and can cooperatively enhance the expression of Runx2
transcription factor, binding to a 30kb upstream enhancer in osteoblasts (Kawane, Komori et
al. 2014).
Moreover, DLX5 appears to be involved in different pathological processes involving
some of the features of ossification such as the ECM mineralization. Yu and co-workers
???????????????????????????????????????????????????????????????????????????????????????????????
via the BMP-2 pathway resulting in increased DLX5 expression and its gene target, Alkaline
Phosphatase (ALP). The BMP-2 dependent DLX5 expression was first observed in vitro
(Ulsamer, Ortuno et al. 2008) where cells stimulated with BMP-2 upregulated the expression
of DLX5 via the SMAD pathway and directly increased DLX5 protein activity via p38
mediated phosphorylation (Ulsamer, Ortuno et al. 2008). Furthermore, DLX5 overexpression
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has been linked with lymphomas and lung cancers where it is hypothesised to regulate MYC
expression (Xu and Testa 2009).
In our experiments, we show that the link between DLX5 and MEF2C is preserved in
HACs, where DLX5 expression is regulated by MEF2C. However, the loss of function
experiments revealed no involvement of DLX5 in SOX9 gene expression. This sheds new
light on the MEF2C function on SOX9 expression, which appears specific and coordinated
????????????????????????????????????????????????????????????????
What specific role the HIF-2?-dependent and MEF2C target gene DLX5 is exerting
in HACs remains to be determined.
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7.1 Introduction
The complex machinery of RNA polymerase II (POL II) is charged with transcribing
most of the protein-coding transcripts (Fuda, Ardehali et al. 2009). The genomic DNA around
and within the coding sequence provides a regulatory code that influences the transcription of
individual genes. This DNA is generally organized in three parts: the core promoter, the
region proximal to the core promoter, and the more distant enhancer sequences. The core
promoter is a target of general transcription factors (GTF) and POL II, the proximal and
enhancer regions are preferentially bound to specific transcription factors (Fuda, Ardehali et
al. 2009).
Gene transcription is a complex and multistep process involving chromatin opening,
assembly of pre-initiation-complex, escaping from the pausing state, elongation, productive
elongation and termination. The status and the local density of the POL II along the gene is
the final target of all regulatory factors. Therefore, the study of the local enrichment of bound
POL II along the gene could provide interesting insights on the intimate biochemical
mechanism where a specific transcription factor is involved (Fuda, Ardehali et al. 2009).
Following a microarray study previously performed in our laboratory (Lafont, Talma et al.
2008), we identified a new hypoxia inducible gene, MEF2C in HACs. Subsequent RNAi
experiments revealed that MEF2C is an important regulator of the HAC phenotype.
Furthermore, the expression of the master regulator gene SOX9 is dependent on MEF2C with
no effects on SOX9 mRNA stability suggesting a transcriptional activation mechanism. As a
consequence, we aimed to determine whether this activation was due to direct binding of
MEF2C protein on the SOX9 gene.
Transcription factors usually have a preference for a set of specific sequences. Given
an identified pool of target sequences, it is possible to build an informatic model that
describes the properties of a specific TF’s targets, which can be used to predict possible
binding sites along the genome (Wasserman and Sandelin 2004). The identification of
regulatory elements is a multilayer procedure that consists of application of bioinformatics
tools to select the candidate sequences followed by an experimental procedure to validate
them (Wasserman and Sandelin 2004).
In this chapter we present the bioinformatic workflow for the determination of
putative MEF2C binding sites on SOX9, POL II local enrichment and the subsequent
validation by chromatin immunoprecipitation (ChIP).
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7.2 Determining putative MEF2C binding sites for the SOX9 gene
MEF2C belongs to the family of MEF2 transcription factors which lie at the centre of
many genetic programmes. The four MEF2 family members (A, B, C, D) have a high
homology in the amino-terminal domain that regulates DNA binding,
interaction/dimerization (MADS domain), and in a domain that regulates protein interaction
(MEF2-like domain). Andres and colleagues determined the communal minimal consensus
sequence of the MEF2 transcription factor in skeletal muscle, cardiac muscle and brain
(Andres, Cervera et al. 1995). MEF2 proteins activate gene transcription by binding to a
communal sequence 5'-CT(A/t)(a/t)AAATAG-3'. It has been hypothesised that MEF2A acts
preferentially as a homodimer whereas MEF2C and MEF2D act as heterodimers (Andres,
Cervera et al. 1995).
In order to find possible MEF2C binding sites within the SOX9 gene a bioinformatic
approach was taken. The gene itself, as well as a 5kb upstream region was taken into
consideration (chromosome 17q24.3, the region tested was 7 kb long). We used different
programs for the screening of putative MEF2C binding sites. The open-source software
JASPAR (http://jaspar.genereg.net) is a collection of putative transcription factor binding
sites modelled as matrices (with a minimum of 80% restriction). These can be converted into
Position Weight Matrices (PWMs), and used for scanning genomic sequences. As a result, we
obtained a list of possible sites, which contained the 5'-CT(A/t)(a/t)AAATAG-3' sequence
and comprises a part of the consensus site to which MEF2 binding has been recognised (FIG
7.2). However, none of the putative sites indicated by the programs turned out to be
conserved between species when analysed with rVISTA software (http://rvista.dcode.org).
Conservation of binding sites across different species could be an important functional
indication of the involvement of that sequence into the regulation of a target gene. However,
we have to also consider that the control of gene expression could be dramatically different
among tissues/organs or different species (Wasserman and Sandelin 2004).
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FIGURE 7.2 Regions tested by ChIP assay. (A) General MEF2 consensus binding sequence. (B) 6
sequences (5 in the proximal-promoter region, 1 in the first intron) have been selected using a specific
Position Weight Matrix for MEF2C. Panel C shows the localisation of the putative binding sites
across the target sequence using the USCS genome browser.
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7.3 Chromatin immunoprecipitation assay (ChIP)
Protein and DNA interaction is necessary to maintain genome integrity and for the
expression of the genetic information. (Dahl and Collas 2008). ChIP assay is an established
tool for studying the DNA-protein. In the classical ChIP assay protein and DNA are
reversibly cross-linked using formaldehyde. Amino and imino groups of amino acids (lysine,
arginine and histidine) and DNA (adenine and cytosine) react with formaldehyde leading to
the formation of cross-links which are fully reversible at high temperature (> 67°C). Cross-
linked genomic DNA is fragmented and then specific antibodies are used to
immunoprecipitate the transcription factors (proteins) together with their bound DNA
fragments. After the final elution, the quantification of potential binding site sequences
enriched is assessed by RT-qPCR and expressed as fold enrichment respect the input
material. Despite the wide range of uses, the ChIP assay has some limitations such as (1)
large cell numbers are required, (2) the long length of the procedure, (3) the reliance on the
ability of antibodies to recognise a potentially cross-linked protein domain. Recently, a new
ChIP technique has been developed to overcome some of these limitations. We here propose
an adaptation of the ChIP protocol published by Dahl and Collas (Dahl and Collas 2008).
This assay has been developed with the aim to reduce the time and the number of cells
needed, a particularly relevant factor when we use primary human cells such as HACs.
In order to obtain cell extract 500,000 HACs were seeded in a 10 cm dish and
cultured for 48 hours in normoxia or hypoxia. Protein/DNA complex was cross-linked with
1% formaldehyde (FA) for 10 min at room temperature and subsequently washed 3 times
with ice-cold PBS. Cells were then collected with a cell lifter and lysed on ice using Lysis
Buffer (see Material and Methods for full details). The cross-linking time was chosen based
on the literature indications (Dahl and Collas 2008). Before the immunoprecipitation step, we
assessed the optimal sonication time for the ChIP assay.
The cell lysate was sonicated for different times, and cross-links were reversed at 68
ºC for 4 hours using complete elution buffer (Materials and Methods). The genomic DNA
was purified using a Chloroform/Isoamyl alcohol protocol and run on a 2% agarose gel to
verify if fragmentation had successfully occurred. The optimal average fragmentation size for
ChIP applications is 500bp which was obtained by sonicating the cells for 8 X 30 seconds
(FIG. 7.3).
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FIGURE 7.3. Optimisation of sonication for ChIP assay. Nuclear extract was sonicated into 500 bp
long fragments using Bioruptor? (Diagenode SA, Belgium). Samples were sonicated for indicated
amounts of time and appropriate DNA Ladders were used to determine fragment sizes. (A) 8 x 30s
sonication gave the desired average fragment size of 500bp. (B) Sonication-induced fragmentation
patterns were consistently reproducible in HAC samples from other donors. Note: bp base pair; s -
seconds. For explanation of the N number see Table 2.2.1.
30ul of magnetic beads were washed 2 times at 4°C with RIPA ChIP buffer (Materials and
Methods) and incubated for 6 hours at 4ºC with 3ug of MEF2C buffer. In a different tube, an
appropriate amount of the normal monoclonal rabbit IgG antibody (used as a negative
control) was added and left for 16 hours incubation at 4ºC. The next day the beads (with
bound antibodies) were washed 3 times with RIPA ChIP buffer solution and finally re-
suspended with the sonicated material in a total volume of 500ul. Following the Dahl and
Collas protocol, one fifth of the starting material was used in the IP step. After the overnight
(o/n) incubation complexes of beads-antibody-protein of interest were washed 3 times for 4
min at 4ºC on a rotating wheel plus a final wash with TE buffer (see Materials and
Methods).The supernatant form the o/n incubated samples was collected and used as INPUT
sample. The complexes of protein-DNA were decoupled from the beads by incubation at
68ºC with the help of Elution buffer. Eluted material was purified using a
Chloroform/Isoamyl alcohol protocol and resuspended in 50 ul of DNA/RNA-free water.
Chapter 7 Study of putative MEF2C binding sites on the SOX9 gene
152
7.4 Quantification of MEF2C binding site enrichment
Once the DNA was isolated, it was quantified using qPCR. This technique is able to
reliably detect small changes in relative levels between samples. Since we used a SYBR-
Green based protocol all the primers were tested for specific amplification using a Melt-
Curve analysis (FIG 7.4). Results were compared between the amounts of material isolated
with MEF2C-specific antibody, a non-specific immunoglobulin G (IgG) and with respect to
the input material. In order to understand if the IP material was the result of genomic DNA
contamination or random antibody binding, an un-related gene sequence was used.
Unfortunately, none of the tested sequences showed an enrichment signal using or
MEF2C-specific antibody that was higher than non-specific binding, quantified with an
unrelated gene sequence (FIG. 7.4.1). To overcome the possibility of low affinity of the
D80C1 to bind formaldehyde-cross-liked epitopes, the ChIP assay was repeated using two
other antibodies (total MEF2 purchased from Santa Cruz C-17X, and anti-MEF2C from
Santa Cruz C-21X). However, both antibodies resulted in the same high background signal
(data not shown).
SEQUENCE PRIMERS 5`- 3`
1 FW TCTGAGGCAAGGAAGAAGGA
RV CTGAGTGTTCCTTCTGCAGC
2 FW GTGTTACAGCCGCCCGAC
RV AAAGATGAGGTGGACGGGAG
3 FW CAGATGAAAACTGCAGTCCATT
RV CCCGTTGATTTGATGCAAGC
4 FW AAGTCATAGCCCTCTTCACTG
RV ATCGGGCAGACATTTTAGCC
5 FW ATAGCTCCGCACTTACCCAA
RV GGCATTGGTGGTGTCTCTCA
A FW GGTAAGTCGAGCAGCAAAGG
RV CCCTCCCCTCCCCTTCTATT
UN-CTR FWAAACAAGCATCAGGGTGGAC
RV GATCCCACAAAGGAAAGGAAC
FIGURE 7.4. Melting curves for amplified regions following ChIP. (A) Primers used to amplify
the various regions under investigation. (B) Melting Curves, which contain a single peak indicating
that the only one (specific) PCR product was amplified in each case.
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FIGURE 7.4.1. ChIP-qPCR analysis of putative MEF2C binding site (sequence 4) on SOX9
gene. (A) Upon reversion of the cross-linking, the DNA was eluted in DNAse-free H2O and the
material obtained was analysed by qPCR. Expression levels have been normalised to the unrelated
control sequence (UN-CTR). Values shown are mean (± S.E.M.) of 4 independent experiments (2
experiments done using passaged cells-N 12, 22; 2 experiments with primary HACs-N 32, 19). Note:
IgG-isotype control.
7.5 Quantification of POL II enrichment on SOX9
In order to understand how MEF2C could affect SOX9 transcription in HACs, in our
next experiments we studied how MEF2C silencing could affect the regional occupancy of
the POL II transcriptional machinery at the SOX9 locus.
Our ChIP protocol was used to measure accumulation of POL II (using specific anti-
POL II antibody) at distal regions of genes compared with the upstream region. This is
considered a hallmark of active transcription (Sandoval, Rodriguez et al. 2004). Then, we
designed primers based on the POL II entry site available from the ENCODE database
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(https://www.genome.ucsc.edu/encode/) which derive from experimental ChIP-SEQ data
(FIG. 7.5). In HACs hypoxic conditions increase the total steady state SOX9 mRNA levels,
without affecting its post-transcriptional stability, thus suggesting a hypoxia-induced
increased rate of SOX9 transcription (see results chapter 5). As a consequence, we expect that
the total amount of POL II at the end of the SOX9 gene is increased in hypoxia compared to
hypoxia. The qPCR quantification of the eluted material revealed that there is a general
increase of POL II at the end the SOX9 gene in hypoxia compared to normoxia, but it did not
reach statistical significance due to the high variability of the data (FIG. 7.5.1 A). The ChIP
assay is a long and multistep procedure and every step could increase the variability of the
results (from the washes after the IP to the sonication) and they can also have an impact on
the final quantification. Furthermore, the fact that different donors have different gene
expression levels adds another variable to the final outcome of the assay.
Subsequently, we tested whether MEF2C silencing affected the accumulation of POL II at the
distal site of the SOX9 gene. MEF2C depleted HACs from 4 different donors (10-60 years
old, average age 25.5 years, 4 males) were cultured in normoxia (20% O2) and hypoxia (1%O
2) for 48 hours and cells were cross-linked for the ChIP assay. At the same time we collected
a portion of the input material in order to assess the effect of MEF2C depletion on SOX9
protein by western blotting. However, results showed that MEF2C depletion had no effect on
POL II enrichment at site C (FIG. 7.5.1 B). SOX9 protein levels were reduced as expected
from previous experiments (FIG. 7.5.1 C).
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SEQUENCE PRIMERS 5`- 3`
A FW GCTCGGACACCGAGAACAC
RV CACACGGGGAACTTGTCCT
B FW GGCTCCAGCAAGAACAAGC
RV GTACTGGTCCGCGAGCTTC
C FW CCTTCGATGTCAACGAGTTTG
RV GTAGCTGCCCGTGTAGGTGA
D FW ACCAGAATTCCCTTTGGACA
RV GGGTACGAGTTGCCTTTAGC
UN-CTR FWAAACAAGCATCAGGGTGGAC
RV GATCCCACAAAGGAAAGGAAC
FIGURE 7.5. SOX9 regions tested by POL II ChIP Assay. Primers have been designed based on
ChIP-SEQ data available in ENCODE database. (A) Primers for four sequences (2 in the proximal
region, 2 in the distal region) have been used to test for POL II occupancy. Panel B shows the
localisation of the 4 putative binding sites across the target sequence using USCS genome browser.
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FIGURE 7.5.1 ChIP-qPCR analysis of POL II enrichment on SOX9 gene. Upon reversion of the
cross-linking the DNA was eluted in DNAse-free H2O and the obtained material was analysed by
PCR. Expression levels have been normalised to the unrelated control sequence (UN-CTR). Values
shown are mean (± S.E.M. ) of 4 independent experiments (2 experiments done using passaged cells;
N 30, 13: 2 experiments with primary HACs N 3, 35). (A) HACs treated with hypoxia for 48 hours
showed enrichment of POL II at the distal site of the SOX9 gene with the highest peak at sequence C.
(B) MEF2C silencing had no effect on POL II recruitment at sequence C. In parallel to ChIP assays a
portion of the input material was taken in order to confirm the expected effect of MEF2C depletion on
SOX9 protein as assessed by western blotting (C). Note: siCTR - control siRNA, IgG-isotype control.
For explanation of the N number see Table 2.2.1.
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7.6 Discussion
The interaction between protein and DNA is required to maintain genome integrity,
replication, repair and for the expression of the genetic information. (Dahl and Collas 2008).
ChIP assay is a powerful tool for studying the DNA-protein interactions in vivo. In recent
decades this technique has been used to unveil the post-transcriptional modification of
histone proteins, chromatin modifiers, DNA associated -non-histone proteins and networks of
transcription factors (Sandoval, Rodriguez et al. 2004, Dahl and Collas 2008).
The major drawback of the ChIP assay is the potentially high unspecific binding
which can be the effect of a poor quality antibody. Another factor that could affect the
binding efficiency is the formaldehyde cross-linking. Antibodies bind with more affinity to
unfixed protein rather than fixed protein which could have the targeted epitope masked by
formaldehyde or by the genomic DNA of the complex DNA/protein. For this reason the use
of polyclonal antibodies is preferred over monoclonal, in order to overcome epitope masking.
ChIP assay was repeated using three different antibodies (total MEF2 purchased from Santa
Cruz C-17X, and anti-MEF2C from Santa Cruz C-21X, D80C1 Cell Signalling) resulted in
the same high background signal. The use of a positive control is recommended for the
assessment of ChIP assay quality, which would consist of an experimentally tested binding
site sequence for the TF under study. However, we were not able to identify a suitable
positive control for MEF2C transcription factor in HACs.
It is relevant that not one of the published studies of MEF2C binding sites has been
done using a human native protein. Furthermore, binding sites could be located at the
downstream region of a gene or in distal regulatory elements (enhancer) (Fuda, Ardehali et al.
2009) and the presence of co-factors or another transcription factors could mask the relevant
epitope for antibody binding and so affect the ChIP assay outcome.
The status and the local density of the POL II along the gene is the final target of all
regulatory factors. In particular , the POL II quantification at the gene distal site of a gene is a
relevant feature of active transcription, the effects of a transcription factor on POL II activity
can be different, for example, by modulation of an important step of the transcription cycle
such as elongation (Fuda, Ardehali et al. 2009). Our attempts to quantify the possible impact
on Pol II distribution along the SOX9 gene in HACs, where the MEF2C protein was silenced,
have been inconclusive. However, it has been demonstrated that, even if POL II is bound to
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the distal end of a gene, it could generate an unproductive transcription (Smallie, Ricchetti et
al. 2010). We believe that further investigation, including possible post-translation
modifications of POL II (phosphorylation Ser-2/activation), is warranted and should lead us
to a deeper understanding of the function of MEF2C in regulation of SOX9 gene
transcription.
At this stage we cannot rule out direct activation of SOX9 transcription by MEF2C,
but we should also consider the possibility that the regulation may be indirect, involving an
(as yet unidentified) factor. Further studies are needed to address these issues
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8.1 Concluding remarks
The maintenance of a specialised phenotype has been long associated with the
activation of a genetic programme that is specific for the unique function of a particular cell
type. Transcription factor (TF) networks play a central role in the expression of specific
genetic patterns via transmission of extracellular (and intracellular) stimuli to the genome,
interaction with the transcriptional machinery and interplay with chromatin remodelling
enzymes (Holmberg and Perlmann 2012, Davis and Eddy 2013, Deneris and Hobert 2014).
Human articular chondrocytes (HACs) are responsible for the functional maintenance
of the articular cartilage tissue. They secrete the specific components of the ECM such as
type II collagen and aggrecan which are critical for the functional competence of the tissue.
Articular chondrocytes are exposed to unique physiological conditions, in particular, high
mechanical stresses and low oxygen levels (hypoxia). Nevertheless, their gene expression
profile is so exquisitely adapted to this particular environment that the lack of oxygen has
actually been shown to be a stimulus for the up-regulation of chondrocyte-specific genes
(Lafont, Talma et al. 2007). Hypoxia initiates a signalling cascade that gives rise to a pro-
????????????? ???????? ??????????? ???????????? ???????? ???? ?????????????? ??? ???? ??? ???????
which in turn triggers the expression of the chondrocyte master regulator SOX9 (Lafont,
Talma et al. 2007, Thoms, Lafont et al. 2009, Thoms, Dudek et al. 2013). In a previous study
we were able to dissect the global effect of hypoxia on the entire chondrocyte transcriptome
(Lafont, Talma et al. 2008). Interestingly, MEF2C, a TF involved in bone development, was
one of the genes correlating strongly with expression of the differentiated chondrocyte
phenotype (Lafont, Talma et al. 2008).
Here, we report a new function of transcription factor MEF2C as a key regulator of
the HAC phenotype.
Using confocal microscopy, we revealed that MEF2C protein is, together with SOX9
???????????? ??????????? ?????????? ?????????????? ??????? ????????????????? ?????????? ???????????
Further investigation revealed that MEF2C expression in HACs is hypoxia inducible. Given
that HIF stabilisation is the earliest and most relevant event in the hypoxic transcriptional
response, we investigated the influence of HIFs on MEF2C expression. Specific silencing of
?????????????????????????????????????????????????????????????????????????????????????????????
partially, of MEF2C expression. Further silencing experiments revealed that TF SOX9
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regulates MEF2C expression in both hypoxia and normoxia. The exact mechanism behind the
??????????? ????????? ??????????? ????? ??? ???? ??????????? ????????????? ??? ????? ???????????
warrants further investigation.
Murine studies have shown that MEF2C is involved in the regulation of bone
development and, together with SOX9, is implicated in regulation of chondrocyte
hypertrophy (Arnold, Kim et al. 2007, Dy, Wang et al. 2012). However, the role of MEF2C
in adult murine cartilage is unknown. By depleting MEF2C mRNA in HACs we discovered
that expression of SOX9 gene was greatly decreased in both normoxia, and in hypoxia. In
hypoxia MEF2C-depleted HACs are not able to up-regulate SOX9 expression and
consequently cannot activate the chondrocyte-specific genetic programme. Furthermore, we
showed that MEF2C is involved in regulation of SOX9 mRNA transcription rather than post-
transcriptional regulation. In fact, in our studies of mRNA stability we demonstrated clearly
that the half-life of SOX9 mRNA is unaltered in MEF2C-depleted HACs. Subsequently, we
tested the hypothesis of a direct binding mechanism of the TF MEF2C on SOX9 via ChIP
assay and the effect on global transcription through the study of the local POL II distribution
on the SOX9 locus. In this respect, our initial attempts were inconclusive, therefore further
work needs to be undertaken to fully elucidate the MEF2C mechanism of action on SOX9
gene transcription.
Interestingly, MEF2C and SOX9 are constitutively expressed and mutually regulate each
other’s expression in HACs in both normoxia and hypoxia. Our results thus demonstrate the
existence a fundamental SOX9/MEF2C directed chondrocyte-specific genetic programme,
?????? ??? ????????? ???? ?????????? ??? ???????? ??????????? ??????????????? ???? ??????????? ?????
again the importance of hypoxia for full expression of the human articular chondrocyte
phenotype (FIG 8.1)
Chapter 8 Concluding remarks and future work
162
FIGURE 8.1 Schematic of the role and regulation of MEF2C in human articular chondrocytes.
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8.2 Future work
8.2.1 Investigate the role of MEF2C in osteoarthritis
Osteoarthritis (OA) is the most common joint disease (Dreier 2010). OA is
characterized by production of matrix-degrading enzymes (aggrecanases, ADAMTSs,
MMPs), which result in the destruction of cartilage matrix and loss of articular cartilage
function (Bau, Gebhard et al. 2002, Goldring and Goldring 2007). Typical hallmarks of OA
are unwanted new bone formation at the joint margins (osteophytes), and changes in
subchondral bone structure (sclerosis) and synovitis. The molecular pathways that influence
the development of this disease are poorly understood. Interestingly, OA chondrocytes can
recapitulate some events of chondrocyte terminal differentiation such as cellular hypertrophy,
matrix mineralisation with the expression of typical hypertrophic biomarkers such as type X
collagen and MMP13, and finally apoptosis (Vondermark, Kirsch et al. 1992, Poole, Nelson
et al. 2003, Kuhn, D'Lima et al. 2004). Recently it has been proposed that transcription
factors like SOX9 and RUNX2 can play a central role in the OA genetic programme
(Orfanidou, Iliopoulos et al. 2009, Brew, Clegg et al. 2010). Interestingly, it has been
demonstrated that type X collagen and RUNX2 are MEF2C targets in murine models; in
addition, we reported in the present study that the TF SOX9 is regulated by MEF2C in
healthy HACs. It would be of interest to investigate if the expression levels, as well as the
sub-cellular localisation, of MEF2C protein are altered in OA cartilage and chondrocytes.
Furthermore, we want to investigate if the function of MEF2C, as a regulator of SOX9 in
healthy HACs is still maintained in OA, or if MEF2C is able to be influence the expression of
type X collagen or RUNX2 in OA human chondrocytes as it is in development
8.2.2 Investigate the role of MEF2C in adult cartilage in vivo
The manipulation of genetically engineered mice has been a very important tool in
understanding the role of transcription factors in cartilage formation. Mef2C+/-, Twist2-Cre
Mef2C loxP/KO, Col2-Cre Mef2C loxP/KO; Mef2c-Engrailed and Mef2c-VP16 murine models
uncovered a role for Mef2c in developing cartilage (Arnold, Kim et al. 2007). However, there
are no data available on the expression and function of Mef2c in adult murine cartilage and
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specifically in the permanent articular cartilage. It will be very interesting to see if Mef2c has
a role in the modulation of articular chondrocyte function in adult mice and in particular its
function as a regulator of Sox9 as we observed in adult HACs.
???????????????????????????? ???????????????????????????????? ?????
expression
???????????????????????????????????????????????????????????????????????????????????
regulators of MEF2C gene transcription in HACs. In order to further understand the
contribution of these transcription factors to MEF2C expression, and to ascertain if they are
able to directly bind to relevant regulatory sequences (i.e. enhancers or the proximal
promoter) in the proximity of MEF2C gene, we will perform ChIP assays. Futhermore, to
??????????? ???? ?????????? ??? ???????????? ??? ????? ???? ??????? ??? ??????????? ??? ??????
transcription, we want to study the role of these individual TFs via transient transfection (or
alternatively via lentiviral mediated transduction) in primary HACs. Moreover, hypoxia
adaptation results in the recruitment of co-activators (e.g. p300 or modifiers of chromatin
structure) or signalling pathways such as MAP kinases. In order to understand the
contribution of specific signalling pathways, experiments using specific inhibitors or siRNA
targeting could be carried out.
8.2.4 Study of the MEF2C pathway
MEF2C plays a central role in the transmission of extracellular stimuli to the genome
where it helps the transcription of cell-specific genes relevant for many cellular phenotypes
such as skeletal muscle, vascular endothelium and chondrocytes (Potthoff and Olson 2007).
As previously mentioned, MEF2C transcriptional activity is classically regulated by the
balance of activating signals from MAPK and inhibiting signals by class II HDACs. Recently
HDACs have been shown to play a role in type II collagen expression and are suggested as a
potential target in OA (Huh, Ryu et al. 2007, Chen, Bao et al. 2010, Culley, Hui et al. 2013,
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Wang, Shih et al. 2013). We would like to study, through already commercially available
inhibitors, the role of HDACs in MEF2C mediated regulation of SOX9 transcription.
Our results indicate that MEF2C positively regulates SOX9 gene expression, most
likely by enhancing (directly or indirectly) SOX9 transcription. However, as underlined in
Chapter 7, the identification of a MEF2C binding site along the SOX9 locus has been
inconclusive thus far. We think that a major drawback of our ChIP-assay was the high
background related to low binding specificity of our MEF2C antibody. To circumvent this we
will investigate the MEF2C transcriptional network using HACs transduced with lentiviral
vectors carrying a tagged MEF2C protein (Addgene, vector 46031: tetO-MEF2C), which
could provide us a stable overexpression of the MEF2C protein and the chance to use anti-
flag/HIS antibodies to pull down MEF2C protein. The analysis of potential binding sites will
be evaluated via specific q-PCR or sequencing (Seq) of the immunoprecipitated material. The
use of lentiviral overexpression of tagged MEF2C coupled with ChIP-Seq could 1) allow us
to uncover the network of genes that are regulated by MEF2C in HACs, and 2) tell us
whether MEF2C overexpression can up-regulate the expression of SOX9 and, consequently,
ECM genes.
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